



UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES

F. EDWARD HEBERT SCHOOL OF MEDICINE

4301 JONES BRIDGE ROAD  
BETHESDA, MARYLAND 20814



SCHOOL OF MEDICINE

APPROVAL SHEET

TEACHING HOSPITALS  
WALTER REED ARMY MEDICAL CENTER  
NAVAL HOSPITAL, BETHESDA  
MALCOLM GROW AIR FORCE MEDICAL CENTER  
WILFORD HALL AIR FORCE MEDICAL CENTER

Title of Thesis: "Early Phase Endotoxin Tolerance: A Study of the Cellular Mechanisms Which Underlie a State of Acquired Refractoriness to Endotoxin-induced Toxic Manifestations."

Name of Candidate: CPT Gary S. Madonna  
Doctor of Philosophy Degree  
December 13, 1985

Thesis and Abstract Approved:

Eleanor S. Metcalf  
Committee Chairperson

3-26-86  
Date

Stephanie N. Vogel  
Committee Member

3-26-86  
Date

John L. McGowan  
Committee Member

3-26-86  
Date

Stephen E. Hargenberger  
Committee Member

3-26-86  
Date

Paul D. Riek  
Committee Member


3-27-86  
Date

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE <b>DEC 1985</b>		2. REPORT TYPE <b>N/A</b>		3. DATES COVERED <b>-</b>	
4. TITLE AND SUBTITLE <b>Early Phase Endotoxin Tolerance: A Study of the Cellular Mechanisms which Underlie a State of Acquired Refractoriness to Endotoxin-induced Toxic Manifestations</b>				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) <b>Uniformed Services University Of The Health Sciences Bethesda, MD 20814</b>				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT <b>Approved for public release, distribution unlimited</b>					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT <b>SAR</b>	18. NUMBER OF PAGES <b>182</b>	19a. NAME OF RESPONSIBLE PERSON
a. REPORT <b>unclassified</b>	b. ABSTRACT <b>unclassified</b>	c. THIS PAGE <b>unclassified</b>			

The author hereby certifies that the use of any copyrighted material in the dissertation manuscript entitled:

"Early Phase Endotoxin Tolerance: A Study of the Cellular Mechanisms Which Underlie a State of Acquired Refractoriness to Endotoxin-induced Toxic Manifestations"

beyond brief excerpts is with the permission of the copyright owner, and will save and hold harmless the Uniformed Services University of the Health Sciences from any damage which may arise from such copyright violations.

A handwritten signature in cursive script that reads "Gary S. Madonna".

CPT Gary S. Madonna, MSC, USA  
Department of Microbiology  
Uniformed Services University  
of the Health Sciences

## ABSTRACT

Title of Dissertation: Early Phase Endotoxin Tolerance: A Study of the Cellular Mechanisms which Underlie a State of Acquired Refractoriness to Endotoxin-Induced Toxic Manifestations

Gary Steven Madonna, M.S.; Candidate, Doctor of Philosophy, 1986

Dissertation directed by: Stefanie N. Vogel, Ph.D., Associate Professor, Department of Microbiology

Endotoxin, the lipopolysaccharide (LPS) cell wall component which is derived from Gram negative bacteria, has been shown to induce a number of toxic manifestations which mimic those seen during systemic Gram negative infection. Hyporesponsiveness to the toxic effects of LPS can be induced for a transient period by pre-exposure of a normally responsive individual to a sublethal dose of LPS. This acquired state of refractoriness to the toxic effects of LPS has been defined as "early endotoxin tolerance". Little is known about the cellular mechanisms that underlie this phenomenon. In this study, an early tolerance system was established by the injection of mice with 25 µg of *Escherichia coli* K235 LPS. Maximal hyporesponsiveness in response to a challenge injection was observed 3 to 4 days after the initial injection, and



normal responsiveness returned by 8 days after the initial exposure to LPS. Further experiments demonstrate that the acquisition and maintenance of the tolerant state coincides temporally with an increase in the number of macrophage progenitor cells in the bone marrow. Cell sizing profiles of the bone marrow cells from tolerized mice indicate that there is an enrichment of a subpopulation of cells that are significantly larger than the cells in bone marrow preparations from control mice. By density gradient sedimentation, it was shown that the denser population of cells from tolerized mice contained the increased numbers of progenitor cells, which, by cytology, were immature monocytic cell types. The increased numbers of macrophage progenitors were sustained after a second (challenge) injection of LPS, but returned to normal levels after multiple tolerizing injections. These results indicate that early endotoxin tolerance is associated with an increase in a population of bone marrow cells that is enriched for macrophage progenitors and suggests the possibility that the lack of responsiveness observed during the hyporesponsive period is related to a failure of these immature cell types to respond to LPS.

Early endotoxin tolerance was inducible in inbred mice which were genetically athymic (T cell-deficient) and in inbred mice which were deficient in a subpopulation of LPS-responsive B cells. In addition, splenectomized mice were capable of being rendered fully tolerant by the protocol established for normal mice. These findings suggest that T cells, Lyb 5

positive B cells and spleen cells do not contribute significantly to the induction of early endotoxin tolerance.

The endotoxin tolerance protocol developed in this study was highly protective against challenge with heterologous preparations of LPS. However, mice which were rendered tolerant to E. coli LPS exhibited a delayed mean time to death following infection with Pseudomonas aeruginosa. However, the tolerance regimen used in this study did not alter the Ps. aeruginosa LD<sub>50</sub> .

Lastly, early endotoxin tolerance could be induced with a non-toxic derivative of Lipid A, monophosphoryl Lipid A (MPL). Associated with MPL-induced tolerance were all of the cellular and protective manifestations observed using intact LPS. These findings underscore the potential of non-toxic LPS derivatives to mitigate the toxic effects of endotoxin.

EARLY PHASE ENDOTOXIN TOLERANCE:  
A STUDY OF THE CELLULAR MECHANISMS WHICH UNDERLIE A STATE OF  
ACQUIRED REFRACTORINESS TO ENDOTOXIN-INDUCED  
TOXIC MANIFESTATIONS

by

Gary Steven Madonna

Dissertation submitted to the  
Faculty of the Department of Microbiology Graduate Program of  
the Uniformed Services University of the Health Sciences  
in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy 1986

## DEDICATION

To God be the Glory!  
Great things He has done:

In my work...

In my family...

In my life...

## ACKNOWLEDGEMENTS

I would like to thank Dr. Stefanie N. Vogel for all she has done for me over the last 3 years. She has helped me advance as a scientist. Her resourcefulness and knowledge has broadened my awareness in the field of immunology. Her leadership, help, and understanding at critical times will always be remembered. Thank you for helping me attain this great goal and capture a new one.

Thank you, United States Army, Medical Service Corps and all the "real soldiers" for allowing me to: "Be, all that I can be, in the Army".

Thanks to the faculty and my advisory committee for the great courses, for all your knowledge imparted, and to the graduate students, all great people.

To our special group in the Vogel lab, I couldn't have done it without you.

Great appreciation goes to: Dr. Marion Fultz, for all the help using the FACS II; Eric Kaufman, for his technical help and friendship; Dr. Cathy Barr, for helping me to set up the columns for polysaccharide separation (over and over); Nancy Coles, for assistance in learning the mouse burn model; Robbie Matthai (Litton Bionetics), who taught me to splenectomize mice and have them live; and to the secretaries, for their encouragement and support.

Thanks Mom (and Dad) for "training me up in the way I

should go". Thanks Mom Henry, for your many prayers, special verses to remember and that special talk that showed me the "real adversary".

Lastly, and most dearly, thanks to my family. Elisa, for your smiles, pretty pictures and understanding. Todd, thanks for admiring me; thanks for being my friend. Sharon, see that, you didn't hold me back after all. We did it together. The best is yet to be.

## TABLE OF CONTENTS

<u>SECTION TITLES AND MAIN SUBTITLES</u>	<u>PAGE</u>
INTRODUCTION AND HISTORY	1
MATERIALS AND METHODS	13
Mice	13
Reagents	14
Measurements of endotoxin sensitivity	16
Determination of numbers of macrophage progenitor cells in the bone marrow and spleen	20
Infection of control and endotoxin-tolerized animals with a Gram negative organism	23
Preparation and analysis of fluorescent antibody-stained cells	24
RESULTS	26
Establishment of an early endotoxin tolerance system	26
Early endotoxin tolerance is associated with alterations in bone marrow-derived macrophage precursor pools	40
Induction of early endotoxin tolerance in other murine models	76
Infection of control and LPS-tolerized ICR mice with a Gram negative organism	95

Induction of early phase endotoxin tolerance by a detoxified Lipid A derivative, monophosphoryl Lipid A (MPL)	101
DISCUSSION	118
BIBLIOGRAPHY	136



## LIST OF TABLES

<u>TABLE NUMBER AND TITLE</u>	<u>PAGE</u>
I. Effect of early phase endotoxin tolerance on clinical endotoxic manifestations	38
II. Effect of initial exposure to <u>E.coli</u> LPS on CSF induced by subsequent challenge with homologous and heterologous LPS preparations	39
III. Effect of purified polysaccharide derived from <u>E. coli</u> LPS on induction of CSF or early endotoxin tolerance	41
IV. Effect of LPS administration on recovery of thioglycollate-induced peritoneal exudate cells	43
V. Differential counts of cytopsin preparations of density gradient-separated Peak 2 cells	59
VI. Percent suppression of control serum CSF response in mice tolerized with homologous or heterologous preparations of LPS	72

<u>TABLE NUMBER AND TITLE</u>	<u>PAGE</u>
VII. LPS-induced serum CSF response in LPS-responsive (C3H/OuJ) and LPS-hyporesponsive (C3H/HeJ) mice	78
VIII. FACS analysis of Thy 1.2+ and IgM+ cells obtained from BALB/c euthymic ( <u>nu</u> /+) or BALB/c athymic ( <u>nu</u> / <u>nu</u> ) mice	85
IX. LPS-induced alterations in bone marrow cell sizing profiles and M-CFU numbers in C3H/HeN and C3.CBA/N ( <u>xid</u> ) mice	91
X. Infection of control and tolerized ICR mice with <u>Pseudomonas aeruginosa</u>	99
XI. Induction of serum CSF in ICR mice injected intravenously or intraperitoneally with MPL	105
XII. Effect of MPL exposure on LPS-induced LD <sub>50</sub> and symptoms of endotoxicity	111

## LIST OF FIGURES

<u>FIGURE NUMBER AND TITLE</u>	<u>PAGE</u>
1. Time course of the induction of early endotoxin tolerance as assessed by LPS-induced CSF	28
2. Determination of the optimal LPS concentration for induction of early endotoxin tolerance	30
3. 24-hour time course for serum CSF production in non-tolerized and tolerized mice	33
4. 24-hour time course for interferon induction in non-tolerized and tolerized mice	35
5. Effect of a tolerizing injection of LPS on the number of nucleated cells and macrophage precursors in the bone marrow	46
6. Effect of a tolerizing injection of LPS on bone marrow cell sizing profiles	49
7. Cell sizing profiles of bone marrow cells obtained at various times after LPS injection	51

FIGURE NUMBER AND TITLE	PAGE
8. Density gradient separation and measurement of M-CFU and HPP activity	54
9. Cell sizing profiles of pooled density gradient-separated bone marrow cells	56
10. Effect of a second injection of <u>E. coli</u> LPS on the number of bone marrow-derived M-CFU	60
11A. Effect of repeated injections of <u>E. coli</u> LPS on the level of serum CSF following LPS challenge	63
11B. Effect of repeated injections of <u>E. coli</u> LPS on the number of bone marrow-derived M-CFU	65
11C. Effect of repeated injections of <u>E. coli</u> LPS on bone marrow cell sizing profiles	68
12A. Effect of repeated injections of <u>Pseudomonas aeruginosa</u> LPS on serum CSF induction by <u>E. coli</u> LPS	70
12B. Effect of repeated injections of <u>Pseudomonas aeruginosa</u> LPS on bone marrow cell sizing profiles	74

FIGURE NUMBERS AND TITLES

PAGE

13.	Effect of the tolerizing regimen on the bone marrow cell sizing profile of inbred LPS-responsive and LPS-hyporesponsive mice	79
14.	Effect of the tolerizing regimen on LPS-induced serum CSF response in BALB/c euthymic (nu/+) and BALB/c athymic (nu/nu) mice	83
15.	Effect of the tolerizing regimen on LPS-induced serum CSF response in C3H/HeN and C3.CBA/N (xid) mice	89
16A.	Effect of the tolerizing regimen on LPS-induced serum CSF in control and splenectomized mice	93
16B.	Bone marrow cell sizing profiles from splenectomized and sham-splenectomized ICR mice following LPS administration	96
17A.	MPL-induction of serum CSF	103
17B.	MPL-induction of early phase tolerance to <u>E. coli</u> LPS	106

FIGURE NUMBERS AND TITLES

PAGE

- |     |   |     |
|-----|---|-----|
| 18. | Interferon induction by MPL and<br>effect of MPL-treatment on<br>LPS-induced interferon production <i>in vivo</i> | 109 |
| 19. | Effect of a tolerizing injection of MPL<br>on the number of macrophage precursors<br>in the bone marrow           | 113 |
| 20. | Effect of tolerizing doses of MPL on<br>bone marrow cell sizing profiles  | 116 |

## INTRODUCTION AND HISTORY

A common feature of all Gram negative bacteria is the presence of lipopolysaccharide (LPS) on the bacterial cell surface. Located exclusively in the outer membrane, this glycolipid is one of the major components through which Gram negative bacteria interact with their environment and, as such, represents a major cell surface bacterial antigen. Gram negative lipopolysaccharides share a basic common structure: a polysaccharide moiety bound covalently to a glycolipid (Westphal and Luderitz, 1954). The polysaccharide component consists of an outermost oligosaccharide polymer or "O-specific chain" which varies among strains of a given genus and is responsible for serotype specificity. This is covalently coupled to an inner "core region" which is composed of a branched oligosaccharide. The composition of the core is common among strains of a given genus, but may vary within different families of bacteria. The core oligosaccharide is attached covalently at a single attachment site (Gmeiner et al. 1971; Sidorczyk et al. 1983; Rosner et al. 1979) to an unusual lipid, Lipid A. In the Enterobacteriaceae, Lipid A consists of a phosphorylated glucosamine disaccharide substituted with ester- and amide-linked long chain fatty acids and represents the least variable region of the LPS molecule.

The synthesis and expression of lipopolysaccharide on the cell surface of Gram negative bacteria has been shown to

play a major role in the pathogenesis of specific enteric diseases. The ability of shigellae to penetrate the epithelial cells of the gut, considered to be the essential step in the pathogenesis of shigellosis, is affected by a number of bacterial surface attributes among which are the chemical composition of the surface lipopolysaccharide O-repeat polymer (Gemski et al., 1972) and the expression of smooth LPS (Gemski and Formal, 1975). LPS expression in Shigella sonnei was shown by Madonna and Allen (1981) to determine the bacterial susceptibility to direct serum bacteriolysis and the opsonification requirements necessary for polymorphonuclear leukocyte-mediated microbicidal action. The loss of sugar components from the O-antigen was also shown to be accompanied by an increased sensitivity to the bactericidal action of antibody and complement in Salmonella (Nelson and Roantree, 1967). Friedberg and Shilo (1970) tested wild-type Salmonella typhimurium and cell wall mutants with deficiencies in their cell wall lipopolysaccharide for sensitivity to the bactericidal action of the lysosomal fraction of polymorphonuclear leukocytes. These investigators found that a complete lipopolysaccharide basal core was essential for resistance to lysosomal bactericidal action, whereas O-specific side chains of the wild type did not enhance resistance. Lastly, Medearis et al. (1968) showed that the presence of lipopolysaccharide side chains in E. coli enabled these organisms to resist phagocytosis.

Endotoxin has also been implicated in the pathogenicity



of the Gram negative diplococcus, Neisseria meningitidis. As in Gram negative rods, the lipopolysaccharide of the meningococcus resides primarily in the outer membrane (Zollinger et al., 1972). Devoe and Gilchrist (1973) showed that during log-phase growth in vitro, this organism over-synthesizes its outer membrane which results in the release of bleblike structures from the surface of the organism. The continuous release of these structures and, hence, endotoxin may play an important role in the severe endotoxic reaction and disease state which ensue. It has also been found that most meningococcal strains express a "rough" LPS, (i.e., no O-antigen; Jennings et al., 1980), although they appear to have the same core and Lipid A components as the Enterobacteriaceae (Jennings et al., 1980). It has been proposed that because meningococcal LPS lacks the high molecular weight O-antigen, it is more likely to bind with platelets and leucocytes which express LPS-binding substances than to remain in body fluids (Springer and Adye, 1975). Although the mechanisms responsible for the production of pathologic changes in meningococcal infection have not been entirely explained, meningococcal endotoxin appears to be responsible for tissue damage, hypotension, vascular collapse and disseminated intravascular coagulation (DIC) seen in fulminant meningococcemia (Beatty, 1983).

Experimentally, investigators have shown that many of the pathophysiologic changes associated with Gram negative sepsis or caused by injection of live or dead Gram negative

bacteria into experimental animals, can also be elicited by injection of purified LPS. Among these are fever (pyrogenicity), hypotension, hypoglycemia, changes in white blood cell counts, disseminated intravascular coagulation, and, if administered in high doses, irreversible (septic) shock and death (Berry, 1977; Galanos *et al.* 1977; Kadis *et al.* 1971; Morrison and Ulevitch, 1978; Nowotny, 1969). It has been shown that Lipid A is responsible for many of these biological alterations. Lüderitz *et al.* (1973) and Weinbaum *et al.* (1971) showed that incomplete lipopolysaccharides from R mutants, which contain predominantly Lipid A, elicited all the biological activities induced by intact lipopolysaccharides. Direct evidence for the biological activity of Lipid A was provided by Galanos and Lüderitz (1975) using electro dialyzed, triethylamine-neutralized, soluble forms of Lipid A derived from Salmonella minnesota R345. The activity of this Lipid A preparation was shown to be comparable to that of intact lipopolysaccharide as assessed by lethality, local Shwartzman reaction, complement activation, and stimulation of B lymphocyte proliferation (Galanos *et al.*, 1977).

The term "endotoxin" was used to describe the toxic, cell-associated LPS molecule, and to differentiate it from classical bacterial exotoxins. However, not all endotoxin-induced changes are pathologic. Some of the effects of endotoxins are clearly beneficial and include such manifestations as immunogenicity, protection against lethal irradiation, immune adjuvant effects, and enhancement of

nonspecific resistance to infection or to toxic doses of endotoxin (reviewed by Nowotny, 1983).

The cellular mechanisms which underlie the induction of these responses by endotoxin have been investigated using experimental models of LPS-hyporesponsiveness. One such model is the C3H/HeJ mouse strain. As a result of a spontaneous mutation which occurred at Jackson Laboratories sometime between 1960 and 1965 (Watson and Riblet, 1974; Glode and Rosenstreich, 1976), C3H/HeJ mice bear a single autosomal mutation,  $Lps^d$  (Watson *et al.*, 1978), which renders them highly refractory to the effects of LPS both *in vivo* and *in vitro* (reviewed by Morrison and Ryan, 1979). It is interesting to note that a defect in LPS sensitivity also arose spontaneously on another inbred background, C57BL/10ScN (Forni and Coutinho, 1978; Vogel *et al.*, 1979), and by complementation studies, appears to be located at the same genetic locus as the C3H/HeJ defect (Watson *et al.*, 1980).

The fact that C3H/HeJ B cells did not respond to LPS to proliferate *in vitro* suggested a possible receptor defect. Forni and Coutinho (1978) and Coutinho *et al.* (1978) described an antiserum which discriminated between responder and nonresponder splenocytes. This antiserum was prepared by injecting rabbits with spleen B cells from C3H/Tif (LPS-responder) mice (two intravenous injections, two weeks apart), collecting the serum one week after the final injection and absorbing the antiserum on C3H/HeJ tissues (pooled liver, thymus, and spleen cells). LPS or free Lipid A, but not two

other B cell mitogens (lipoprotein and purified protein derivative of tuberculin), competed with the antiserum for binding to the B cell surface membrane which suggested a Lipid A receptor defect. However, when Kabir and Rosenstreich (1977) compared the binding of  $^{14}$ C-labeled LPS from Salmonella minnesota to splenic lymphocytes from C3H/HeN (LPS-responsive) and C3H/HeJ (LPS-hyporesponsive) mice, they found that spleen cells from both strains bound LPS equally well. Further, a highly lipophilic, polysaccharide-deficient glycolipid from S. minnesota R595 was shown to bind cells at least 20 times better than did smooth LPS. This binding was enhanced by trypsin or neuraminidase treatment. These data suggested to the authors that LPS binds via a nonspecific interaction between its lipid moiety and some lipid component of the cell membrane.

Jacobs (1984) used a sensitive hapten-sandwich immunofluorescence technique and at the single cell level showed that a positively charged membrane protein is responsible for the initial interaction of LPS with murine lymphocytes. As such, C3H/St (Lps<sup>n</sup>) splenic lymphocytes, pre-treated with pronase or the cross-linking reagent paraformaldehyde, lost the ability to bind LPS. Additionally, when the LPS-cell interaction was carried out at pH 4.5 (which increases the number of positively charged imidazole groups) the number of LPS positive cells which were detected was increased. Zimmerman et al. (1977) and Kern (1984) compared the binding of iodinated Lipid A to splenocytes from C3H/HeN and C3H/HeJ mice using an immunofluorescence-autoradiography

procedure. Like Kabir and Rosenstreich (1977), who used intact LPS, Kern found that the strains were indistinguishable on the basis of binding and also noted that spleen cells from the responder strains, but not the non-responder strain, proliferated in the presence of Lipid A. This group postulated that a separation of LPS-binding and LPS-triggering sites could account for the discrepancies between the findings of Coutinho *et al.* vs. those who had measured binding of LPS to cells directly, and that C3H/HeJ mice had retained the capacity to bind LPS but had lost the capacity to be triggered.

One of the strongest lines of evidence to support the hypothesis that a membrane defect results in a functional defect in C3H/HeJ mice comes from the studies of Jakobovits *et al.* (1982). Using fusogenic membrane vesicles, these investigators inserted the membrane components from lymphocytes which respond to LPS ( $Lps^n$ ) into the membranes of C3H/HeJ spleen cells. They found that the latter could now be stimulated by LPS, and suggested that the inability to respond was due to the lack of suitable membrane constituents.

Although the  $Lps$  gene defect has not been fully delineated, experiments using C3H/HeJ mice, in conjunction with syngeneic, fully LPS-responsive ( $Lps^n$ ) strains, have provided strong evidence that the pathophysiologic changes which result from LPS administration are mediated indirectly by a number of immunoregulatory factors [e.g., endogenous pyrogen (Atkins *et al.*, 1967), tumor necrotizing factor (Mannel *et al.*, 1980), colony-stimulating factor (Apte *et al.*, 1976; Apte and Pluznik,



1976; Metcalf, 1971; Quesenberry et al., 1972), glucocorticoid antagonizing factor (Moore et al., 1976), and prostaglandins (Skarnes and Harper, 1972)] produced by macrophages in response to LPS. Furthermore, agents which activate macrophages, either in vivo (Suter et al., 1958; Benacerraf et al., 1959) or in vitro (Moore et al., 1980; Rosenstreich and Vogel, 1980), increase sensitivity to LPS, even in the C3H/HeJ mouse strain (Vogel et al., 1980).

A second model of murine endotoxin hyporesponsiveness is a state of endotoxin refractoriness which is acquired after exposure of a normally sensitive animal to a sublethal injection of endotoxin. The acquisition of such a state of resistance was first encountered nearly 100 years ago when whole bacterial vaccines were used to induce "therapeutic fever" in the treatment of certain diseases. It was found that increasing quantities of typhoid vaccine were required in order to maintain elevated temperatures (Heyman, 1945). Acquired resistance to alcohol-fractionated pyrogenic preparations, initially shown by Centanni (1894), was demonstrated by reduced fever-inducing activity in animals given repeated injections of these preparations. Centanni (1942) also demonstrated that this pyrogenic substance was stable to heat and was not protein in nature. Favorite and Morgan (1942) were the first to use the term "endotoxin tolerance" to describe this phenomenon. They also noted that the presence of anti-LPS antibodies did not correlate with such resistance. These findings led them to postulate that such acquired resistance had a nonimmunologic

basis. The development of tolerance to LPS-induced lethality was also noted by Wharton and Creech (1949). In their studies, tolerance was shown to be induced in mice following a single injection of endotoxin, to peak three days later, and was shown not to correlate with anti-LPS antibody titers. Beeson (1946, 1947a, 1947b) showed that: (1) "endotoxin tolerance" could not be transferred by serum, (2) the acquisition of tolerance was accompanied by enhanced blood clearance of endotoxin and, (3) blockade of the reticuloendothelial system (RES) with thorotrast (thorium dioxide) retarded clearance of endotoxin and abolished tolerance.

Up to this time, endotoxin-induced fever was thought to be the result of a direct effect of LPS on the thermoregulatory center of the brain. In 1948, Beeson provided evidence that endotoxin stimulated "host cells" to release an intermediate factor, endogenous pyrogen (EP), which acted on thermoregulatory centers in the brain to evoke fever. After Beeson (1948) reported the extraction of EP from rabbit polymorphonuclear leukocytes, these cells were considered to be the major source of pyrogen for the next 20 years. Thus, until EP was shown to be a macrophage secretory product by several groups (Atkins *et al.*, 1967; Hahn *et al.*, 1967; Murphy *et al.*, 1980), tolerance to the pyrogenic effects of endotoxin was thought to result from enhanced uptake of endotoxin by the RES which diverted the endotoxin away from EP-producing cells.

In 1965, Greisman and Woodward provided evidence for two distinct mechanisms of endotoxin tolerance which were

described temporally as "early phase" and "late phase" endotoxin tolerance. The concept of an early phase of tolerance was based on experiments in man, in which a refractory state was observed within hours after continuous intravenous infusion of endotoxin and, in rabbits, by 24 hours after a single injection. This type of hyporesponsiveness was shown to be specific for endotoxins as a class (e.g., tolerance was not induced for other pyrogens, such as staphylococcal enterotoxin), was not transferable with serum, and was found to wane over subsequent days. A later phase of tolerance to the pyrogenic effects of endotoxin could be demonstrated if endotoxin were re-administered after 5 days. Unlike early phase tolerance, this late phase was shown to be transferable with serum and exhibited marked O-antigen specificity. Thus, the early phase of pyrogenic tolerance was hypothesized to reflect a decreased capacity of macrophages to release EP, and late tolerance to be mediated by specific humoral antibodies. By passive transfer experiments, Greisman and Woodward (1965) and Greisman et al. (1966) showed that pyrogenic quantities of endotoxin were present in the serum of tolerized animals. These findings indicated that early phase tolerance was not mediated simply by clearance of endotoxin from the circulation.

As with early tolerance to fever induction, an early phase of endotoxin tolerance for the lethal effects of LPS was demonstrated in mice 24 hours after a single intraperitoneal or intravenous injection of endotoxin (Abernathy, 1967; Urbaschek and Nowotny, 1968; Wharton and Creech, 1949; Williams et al.,



1983). Early tolerance to a lethal challenge with LPS also extends to endotoxins of various Gram negative bacteria. Thus, no O-antigen specificity was seen during early tolerance.

As in the case of the genetically LPS-hyporesponsive C3H/HeJ mouse, studies of early endotoxin tolerance in animals have indicated a central role for the macrophage. Dinarello and co-workers (1968) showed that isolated Kupffer cells from rabbits [shown previously by Braude *et al.* (1955) and Cremer and Watson (1957) to be the primary site of endotoxin localization following i.v. injection] were stimulated by LPS to produce EP. However, isolated hepatic Kupffer cells from rabbits rendered tolerant by a previous LPS injection were found to be refractory to stimulation by LPS to release EP *in vitro*. Cellular refractoriness to endotoxin was also shown in human blood monocytes. These cells normally respond to LPS with release of large amounts of colony-stimulating activity (Sullivan *et al.*, 1983); however, within 72 hours of a second exposure of endotoxin, a marked reduction in release of this factor was observed. In addition, Rietschel *et al.* (1982) showed that peritoneal macrophages from tolerant animals secreted substantially lower levels of prostaglandins ( $\text{PGE}_2$  and  $\text{PGF}_{2\alpha}$ ) than peritoneal cells from control animals. Lastly, Williams *et al.* (1983) suggested that an interaction of macrophages and splenic nonadherent cells were required for the early tolerant state.

The goal of this study was to probe further the cellular mechanisms which accompany a state of early endotoxin

tolerance. To this end, a model system, based on that described by Williams et al. (1983), was established using highly purified endotoxin derived from Escherichia coli K235. Using this model system, a state of early phase endotoxin tolerance was found to be associated with marked alterations in bone-marrow derived macrophage progenitor pools. The cellular mechanisms which underlie the establishment of early tolerance were analyzed in mice which were genetically LPS-hyporesponsive, T cell deficient, B cell deficient, or asplenic. Further experiments were carried out to investigate whether induced hyporesponsiveness to LPS rendered mice refractory to infection by a Gram negative organism, Pseudomonas aeruginosa. Lastly, a non-toxic derivative of Lipid A, monophosphoryl Lipid A, was assessed for its efficacy as an inducer of early endotoxin tolerance.

## MATERIALS AND METHODS

MICE -- Outbred, female HSD(ICR)BR mice (ICR) were used for the majority of the studies described herein and were obtained from Harlan Sprague Dawley (Indianapolis, IN). For some experiments, inbred C3H/OuJ ( $Lps^n$ ) and C3H/HeJ ( $Lps^d$ ) mice were obtained from the Jackson Laboratories (Bar Harbor, ME). For experiments which involved the use of athymic (nude) mice, BALB/c ( $\nu/\nu$ ), and their euthymic littermates, BALB/c ( $\nu/+$ ), were obtained from Harlan Sprague Dawley (Indianapolis, IN). T-cell deficiency was verified in BALB/c ( $\nu/\nu$ ) mice using fluorescence activated cell sorter (FACS) analysis as described below. Female C3H/HeN mice (Harlan Sprague Dawley, Indianapolis, IN) were age-matched with female, congenic C3.CBA/N ( $xid/xid$ ) mice. The latter were bred at the Uniformed Services University of the Health Sciences (Bethesda, MD) and were the kind gift of Dr. James Kenny, Dept. of Microbiology, Uniformed Services University of the Health Sciences. In an attempt to minimize potential environmental differences due to the different sources of these two strains, C3H/HeN and C3.CBA/N mice were housed in the same room for 2 weeks prior to treatment.

In one series of experiments, ICR mice were splenectomized. Splenectomies were performed as follows: Mice were given general anesthesia (Metofane (Methoxyflurane), Pitman-Moore, NJ). Each spleen was removed after the arteries and veins which supply the spleen were tied off with 4.0 silk

suture. The peritoneal lining was closed with 4.0 silk suture and the skin brought together and fastened with 9 mm autoclips (Clay Adams, Becton Dickinson, Parsippany, NJ). Sham splenectomies were also carried out in a similar fashion except spleens were gently lifted out of the peritoneal cavity without severing the vessels and were replaced immediately prior to closure. The mice were allowed to recover from surgery for seven days prior to treatment.

All mice were used at 6-8 weeks of age. Mice were housed in cages with Micro-Isolator Unit tops (Lab Products, Rockville, MD) in a negative pressure Horsfall Isolator Unit (Hazelton Systems Inc., Aberdeen, MD), and were fed RMH 3000 mouse chow (Agway, Inc., Syracuse, NY) and acidified water ad libitum.

#### REAGENTS

Endotoxin preparations -- Protein-free, phenol-water extracted LPS, from Escherichia coli K235 L+OC+ (serotype O1:K1:HNM, Barry et al., 1962), was prepared by the method of McIntire et al. (1967). Pseudomonas aeruginosa F-D type I LPS was obtained from List Biological, Inc. (Campbell, CA). Phenol-water extracted Salmonella typhimurium LPS and Bacteroides fragilis LPS were the kind gifts of Dr. Suzanne Michalek (Univ. of Alabama, Birmingham, AL). Each LPS preparation was prepared in pyrogen-free saline at a final concentration of 1 mg/ml and was put into solution by

sonication (three, 5 sec bursts) using a Sonifier Cell Disrupter, Model W185 (Heat Systems, Ultrasonics, Inc., Plainview, NY) with a microtip and a setting of 3 on the output control.

Detoxified endotoxin (monophosphoryl Lipid A, Lot 375), derived from a heptose-less mutant of *S. typhimurium* G30/C21 (Qureshi *et al.*, 1982), was obtained from Ribi ImmunoChem Research, Inc. (Hamilton, MT). The monophosphoryl Lipid A (MPL), 1 mg/vial, was solubilized by addition of 0.5 ml sterile distilled water, followed by swirling of the suspension in a 65-70°C water bath for 10-20 seconds, and sonication for 10-20 seconds. After three to four cycles of heating and sonication, the solution clarified to slight opalescence. To this solution was added 0.5 ml of 3.6% NaCl to give a final stock solution of MPL (1 mg/ml) which was subjected to one additional cycle of heating and sonication.

Preparation of lipid-free polysaccharide -- Phenol-water extracted *E. coli* K235 LPS was subjected to acid hydrolysis [1.0% (approximately 0.17 N) acetic acid, 100°C, 4 h], centrifuged to pellet insoluble Lipid A, and the soluble polysaccharide-rich supernatant removed and dried (Galanos *et al.*, 1971). The polysaccharide fraction was further separated from any remaining LPS by gel chromatography on a Sephadex G-25-300 (Sigma, St. Louis, MO) column (60 x 1.5 cm) which was equilibrated in a solution which consisted of 0.4% (v/v) pyridine (Baker Chemical Co., Phillipsburg, NJ) and 1.0% (v/v) glacial acetic acid (Mallinckrodt Inc., Paris, KY) in water

(Jansson et al., 1981). Those fractions which contained the polysaccharide were identified by detection of glucose using the phenol-sulfuric acid method (Dubois et al., 1956).

Fractions which contained polysaccharide were then pooled and dried in vacuo. The final polysaccharide preparation was adjusted by total glucose content to be equivalent to the glucose content of the phenol-water extracted E. coli LPS prepared at a final concentration of 1 mg/ml. Mice were injected with 25  $\mu$ g/mouse of E. coli K235 LPS or the dilution of purified polysaccharide which was equivalent in glucose content to that of 25  $\mu$ g E. coli LPS.

#### MEASUREMENTS OF ENDOTOXIN SENSITIVITY

Measurement of colony stimulating factor (CSF) activity in serum -- After injection of saline or endotoxic preparations into mice, sera were collected. CSF activity in the sera was determined using a bone marrow colony assay in semi-solid agar (Williams et al., 1983). Blood from mice in each experimental group was collected from the orbital plexus 6 h after injection, pooled, and the serum obtained after clot formation and centrifugation (1500 x g, 10 min) in a Beckman Microfuge 12 (Palo Alto, CA). Serial dilutions of serum were prepared in serum-free RPMI 1640 (M.A. Bioproducts, Walkersville, MD) supplemented with penicillin/streptomycin (100 IU/ml and 100  $\mu$ g/ml, respectively; Gibco Laboratories,



Chagrin Falls, OH), 15 mM HEPES buffer (Research Organics Inc., Cleveland, OH), 2 mM glutamine (Gibco Laboratories, Grand Island, NY), and 0.2% sodium bicarbonate (Fisher Scientific Co., Fair Lawn, NJ). Two tenths ml of each serum dilution was added to each of two tissue culture wells (35 mm diameter) in 6 well tissue culture plates (Costar, Cambridge, MA).

LPS has been shown to interfere with the colony assay (Moore *et al.*, 1980). For this reason, bone marrow cells for the CSF colony assay were obtained from endotoxin hyporesponsive C3H/HeJ ( $Lps^d$ ) mice, to preclude possible effects of endotoxin carried over in serum samples. Femurs and tibias were homogenized in ice cold RPMI medium using a mortar and pestle. Bone fragments and cell aggregates were allowed to settle in a conical centrifuge tube. The crude cell suspension was enriched for mononuclear cells by density gradient centrifugation ( $400 \times g$ , 20 min,  $20^\circ C$ ) in Lymphocyte Separation Medium (LSM; Litton Bionetics, Charleston, SC) using a Sorvall RT 6000 refrigerated centrifuge (Dupont Co., Wilmington, DE). The cells collected from the interface of the LSM gradient were washed twice in RPMI medium supplemented with 10% fetal calf serum and were enumerated using a Coulter Counter Model ZM (Coulter Electronics Ltd., England). Bone marrow cells were diluted to a final concentration of  $1 \times 10^5$  cells per ml in molten colony assay medium (RPMI 1640 supplemented with glutamine, HEPES buffer, sodium bicarbonate, penicillin/streptomycin, 15% fetal calf serum (M.A. Bioproducts), and 0.3% Bacto-agar (Difco Laboratories, Detroit,

MI)). One milliliter of this suspension was then added to each of the wells which contained 0.2 ml of serial serum dilutions, mixed by swirling, and allowed to solidify. The cell cultures were then incubated at 37°C (5% CO<sub>2</sub>) for 7 days, at which time bone marrow colonies (>50 cells/colony) were counted under an inverted microscope at 40X magnification. Serum CSF activity is based on the linear part of the dilution curve and is expressed as colony forming units (CFU) per ml of serum.

Interferon production and assay -- To measure the level of interferon in serum after administration of saline or endotoxic preparations, blood samples were collected and processed as described for the collection of serum for CSF activity. Interferon activity was measured by an antiviral assay (Rubinstein et al., 1981) modified as described elsewhere (Vogel et al., 1982). Two-fold serial dilutions of serum samples were prepared in a final volume of 50 µl of assay medium (Minimal Essential Medium Eagle (M.A. Bioproducts, Walkersville, MD) supplemented with antibiotics, HEPES buffer, glutamine and 10% fetal calf serum) in flat-bottomed, 96-well Falcon culture dishes (Becton Dickinson, Oxnard, CA). To each well was added 10<sup>5</sup> L929 fibroblasts in a volume of 50 µl. The supernatants were aspirated after a 24 h incubation at 37°C (5% CO<sub>2</sub>) and the cells infected with 100 µl per well of Vesicular Stomatitis Virus (Indiana strain) in medium containing 10% fetal calf serum at a multiplicity of infection of approximately 0.1. At 24-48 h post-infection, complete cytopathic effect was observed microscopically in infected



medium-treated control cells. The cells were then washed with cold Earle's Balanced Salt Solution (Gibco Laboratories, Grand Island, NY) and fixed for 10-30 min with 5% formaldehyde (Fisher Scientific Co., Fair Lawn, NJ). The cells were stained for 5 min with 0.05% crystal violet (Sigma Chemical Co., St. Louis, MO) in 20% ethanol, and subsequently washed with tap water. Optical density was measured at 595 nm using an ELISA reader (Biotek, Inc., Burlington, VT). Three controls were included for each assay: (i) medium-treated, uninfected L929 cells (cell control); (ii) medium-treated, virus-infected L929 cells (virus control); and (iii) a titration of NIH mouse fibroblast interferon reference standard (G-002-904-511; Research Resources Branch, National Institute of Allergy and Infectious Diseases, NIH) adjusted to 100 U/ml. The first dilution of a sample which exhibited an optical density equal to that of the virus control wells (i.e., no interferon protection) was defined as the endpoint. Reciprocal titers (expressed as units per milliliter) were calculated based on the titration of the NIH standard.

Determination of 50% lethal dose (LD<sub>50</sub>) -- Mice (20 mice/group) were injected intraperitoneally with either saline, *E. coli* K235 LPS (25 µg/mouse), or MPL (100 µg/mouse) on day 0. Three days later, five mice from each group were challenged i.p. with either 3000, 1500, 750, 375, or 187 µg of *E. coli* LPS in 0.5 ml of pyrogen-free saline. Deaths were recorded daily for 3 days. The LD<sub>50</sub> for each experiment was calculated by the

method of Reed and Muench (1939).

Assessment of endotoxin-induced symptoms -- Mice were assessed for visual manifestations of endotoxicity as described by Pier et al. (1981). Accordingly, mice were observed for ruffled fur, conjunctival discharge, and diarrhea 6 h following administration of 25 µg/mouse of endotoxin.

#### DETERMINATION OF NUMBERS OF MACROPHAGE PROGENITOR CELLS IN THE BONE MARROW AND SPLEEN

Preparation of bone marrow cells -- Groups of 5 mice were injected with either saline, LPS, or MPL as indicated. Five femurs per group (one per mouse) were homogenized using a mortar and pestle with 3 changes of ice cold (4°C), serum-free RPMI 1640 (supplemented with antibiotics, HEPES buffer, and glutamine). The cell suspension was collected in a 15 ml conical centrifuge tube and brought to final volume of 15 ml. The suspensions were vortexed and were incubated on ice for 10 min to allow for settling of bone fragments and cell aggregates. The top 10 ml of cells were then transferred to a second tube and kept cold (4°C) until cultured. A sample of this cell suspension was used to obtain a nucleated cell count and cell sizing profile using a Coulter Counter Model ZM and Coulter Channelyzer C1000 equipped with a Coulter X-Y Recorder 4 (Coulter Electronics, Inc., Hialeah, FL), which was

calibrated according to the manufacturer's instructions.

Preparation of spleen cells -- Groups of mice were injected with saline or LPS as indicated. Single cell spleen suspensions were prepared from five spleens per experimental group by mascerating spleens on 40 mesh stainless steel screens. The cells were resuspended in ice-cold, serum-free RPMI 1640 (supplemented with antibiotics, HEPES buffer, and glutamine). A sample of each cell suspension was used to obtain a nucleated cell count employing a Coulter Counter Model ZM. These spleen cell suspensions were then used for determination of the number of macrophage progenitor cells.

Assay for macrophage progenitor cells -- The number of macrophage progenitor cells (macrophage colony forming units, M-CFU) in each bone marrow or spleen cell suspension was determined by the method of MacVittie (1979) using a double layer, semi-solid agar colony assay in 60 mm x 15 mm grided tissue culture dishes (Nunc, Roskilde, Denmark). The bottom layer in each culture dish was comprised of approximately 7000 U of macrophage-specific colony stimulating factor (CSF-1) in 2.5 ml of 0.5% Bacto-agar (Difco Laboratories, Detroit, MI) in medium composed of tryptic soy broth and CMRL 1066 supplemented with fetal bovine serum, horse serum, an antibiotic/antimycotic mixture, serine, L-asparagine, sodium pyruvate and sodium bicarbonate as described (MacVittie, 1979). The CSF-1 used was partially purified to insure removal of contaminating

interferon (Warren and Vogel, 1985). The upper layer contained  $5 \times 10^4$  nucleated bone marrow cells from each cell suspension in 2 ml of 0.33% agar in medium. Duplicate cultures were incubated at  $37^\circ\text{C}$  (5%  $\text{CO}_2$ ) for 10 days and colonies ( $>50$  cells) counted.

To test for the presence of more primitive macrophage precursors which exhibit high proliferative potential (HPP), the bottom layer contained CSF-1 and 10% human spleen conditioned medium (HSCM). Human serum (20%) was included in both top and bottom layers. HSCM provides a source of "Synergistic Activity" (SA), shown by Bradley and Hodgson (1979) to be essential for HPP development. HSCM was the kind gift of Dr. Thomas MacVittie (Armed Forces Radiobiology Research Institute, Bethesda, MD), and its preparation has been described elsewhere (Metcalf and Johnson, 1981). HPP colonies fail to develop in the presence of CSF alone (Bradley and Hodgson, 1979), but in the presence of both CSF and SA will produce very large macrophage colonies ( $>2$  mm diameter) which are readily distinguishable from M-CFU by size and are counted after 12 days of incubation.

Separation of bone marrow cells by density gradient sedimentation -- In some experiments, ICR mice were injected with either saline or *E. coli* LPS and after 3 days their bone marrow cells collected and separated by unit gravity sedimentation (Bertoncello et al., 1981) in a 60 ml separatory funnel. One  $\times 10^7$  cells from groups of five mice were

resuspended in 10 ml of RPMI 1640 (supplemented with glutamine, HEPES buffer, sodium bicarbonate, antibiotics and 10% fetal calf serum) and layered onto a 50 ml gradient. The gradient was poured stepwise in four 12.5 ml volumes (which consisted of 30%, 25%, 20%, and 15% fetal calf serum in RPMI medium) layered onto a 10 ml cushion of 50% fetal calf serum in RPMI 1640 supplemented as indicated above. Cells were allowed to sediment at 4°C for 3.5 h. Three ml fractions were collected dropwise from the bottom of the gradient, centrifuged, and the cell pellets resuspended in 0.5 ml of 10% fetal calf serum in RPMI 1640 medium supplemented as indicated above. Nucleated cell counts and cell sizing profiles were then obtained from each fraction and the number of M-CFU or HPP in individual or pooled fractions was determined as described above.

#### INFECTION OF CONTROL AND ENDOTOXIN-TOLERIZED ANIMALS WITH A GRAM NEGATIVE ORGANISM

Bacteria -- Pseudomonas aeruginosa, type I was grown overnight at 32°C in Trypticase Soy Broth (TSB) (Difco Laboratories, Detroit, MI). Four tenths ml of this overnight cell suspension was used to inoculate 65 ml of TSB which was further incubated at 32°C with shaking. Bacterial growth was monitored every 0.5 h using a Spectronic-20 (Bausch and Lomb, Rochester, NY) at OD<sub>660</sub>. At OD<sub>660</sub> = 0.25, the late log phase cells were washed and resuspended in saline to OD<sub>660</sub> = 0.6 (2-5



$\times 10^8$  viable bacteria/ml). Ten-fold dilutions were then made in saline for injections of mice and appropriate dilutions plated on Trypticase Soy Agar (Difco Laboratories, Detroit, MI) to obtain viable cell counts.

Injection protocol -- Mice were injected with saline (control) or LPS (tolerized) on day 0. On day 2, the lower back of each mouse was shaved. On day 3, each mouse was anesthetized with Metofane (Methoxyflurane, Pitman-Moore, NJ) and a third degree burn inflicted by igniting 0.4 ml of 95% alcohol on a 2.5 x 2.5 cm area of exposed bare skin (the area exposed in an asbestos template) (Stieritz and Holder, 1975; Pavlovskis et al., 1977). After 10 sec, the flame was extinguished and 0.5 ml of each 10-fold dilution of bacteria injected subcutaneously at the burn site (5 or 10 mice/bacterial dilution). Deaths were recorded daily for one week.

#### PREPARATION AND ANALYSIS OF FLUORESCENT ANTIBODY-STAINED CELLS

Individual spleen cell suspensions from five athymic BALB/c (nu/nu) mice and five euthymic BALB/c (nu/+) mice were prepared in Hank's Balanced Salt Solution (without phenol red; Gibco Laboratories, Chagrin Falls, OH) supplemented with 10% newborn calf serum (Gibco Laboratories, Grand Island, NY) and 0.4% (w/v) sodium azide (Matheson Coleman and Bell, Norwood, OH). Following lysis of erythrocytes with an ammonium chloride

lysing solution (AKC-lyse, M.A. Bioproducts, Walkersville, MD), aliquots of each cell suspension were treated with fluoresceinated (FITC) chicken anti-mouse  $\mu$  polyclonal antibody, FITC-anti-Thy 1.2 antibody (a monoclonal rat IgG2b; Becton Dickinson, Sunnyvale, CA), or a control antibody, FITC-CBPC-101 (a monoclonal IgG2b that does not react with murine cells) at a final concentration of  $1 \mu\text{g}$  antibody/ $10^6$  cells. Both the FITC-chicken anti-mouse  $\mu$  and FITC-CBPC-101 antibodies were the kind gifts of Dr. Fred Finkelman, Dept. of Medicine, U.S.U.H.S. Fluorescence analysis was carried out using a fluorescence-activated cell sorter (FACS II; Becton Dickinson, Mountain View, CA) in the laboratory of Dr. Lyn Yaffe (Dept. of Pathology, Navy Medical Research Institute, Bethesda, MD). Cells were assigned to fluorescence intensity channels ranging from 1 to 1024 according to the amount of surface-bound fluorescein label detected. For each sample, the percentage of cells which stained with a specific antibody and the median fluorescence intensity (MFI) of the staining were determined by a computer program of curve subtraction and integration as described previously (Mond *et al.*, 1980).



## RESULTS

### ESTABLISHMENT OF AN EARLY ENDOTOXIN TOLERANCE SYSTEM

Previous studies have shown that injection of LPS into mice resulted in a rapid rise in serum CSF which reached a maximum level at approximately 6 h post-injection (Metcalf, 1971). In a recent report by Williams *et al.* (1983), this manifestation of endotoxin responsiveness was found to be mitigated in mice challenged with LPS 3-4 days after an initial sublethal exposure to LPS. The first series of experiments described herein sought to optimize conditions under which this state of "early endotoxin tolerance" was inducible.

Establishment of early endotoxin tolerance in outbred ICR mice with E. coli K235 LPS -- An 8 day time course experiment was carried out in which groups of outbred ICR mice were injected intraperitoneally with either *E. coli* K235 LPS (25  $\mu$ g/mouse) or saline. This dose of LPS was chosen based on previous studies by Williams *et al.* (1983) in which *E. coli* O55:B5 LPS was used to induce early endotoxin tolerance in this mouse strain. On successive days following an initial injection, individual groups of mice were challenged with *E. coli* K235 LPS (25  $\mu$ g/mouse) and bled 6 h later for serum which was subsequently tested for the presence of CSF. The ability of mice to respond to a second (challenge) injection of LPS was

most suppressed at 3 and 4 days after the initial exposure to LPS (Figure 1). After this time, tolerance (hyporesponsiveness to LPS) gradually waned, as indicated by the return of near-normal CSF production by day 8. Groups of mice injected with saline on day 0 responded to an injection of *E. coli* LPS with high levels of CSF throughout the 8 day time period. These results confirmed those of Williams *et al.* (1983).

Maintaining a 3 day period between the initial and challenge doses of LPS, the concentration of LPS used for the initial injection was varied to determine the optimal amount of LPS which rendered the mice most hyporesponsive to a subsequent LPS challenge. Figure 2 illustrates that tolerance, as assessed by a decreased capacity to produce serum CSF, was induced over a wide dose range of *E. coli* K235 LPS (6.25  $\mu$ g - 100  $\mu$ g/mouse) but optimally at 50  $\mu$ g/mouse. However, 50  $\mu$ g/mouse was occasionally lethal, so a lower dose of 25  $\mu$ g/mouse was used in all subsequent experiments. The level of CSF induced by one injection of LPS (25  $\mu$ g/mouse) was the same if administered intraperitoneally or intravenously (i.p. =  $4,320 \pm 565$  vs.  $4,520 \pm 201$  CFU/ml serum). With respect to tolerance induction (as assessed by suppressed CSF activity), little difference in the degree of suppression induced was observed if the LPS were administered intraperitoneally (89% suppression) or intravenously (82% suppression). This confirmed findings which were previously reported by Williams *et al.* (1983).

To insure that the 6 h time point used in initial

Figure 1. Time course of the induction of early endotoxin tolerance as assessed by LPS-induced CSF --- ICR mice were injected i.p. with either saline or *E. coli* LPS (25  $\mu$ g/mouse). At intervals of 1 to 8 days, mice (5 mice/group) were challenged i.p. with a second injection of *E. coli* LPS (25  $\mu$ g/mouse). Six hours later, the mice were bled and their sera pooled and assayed for CSF activity as described in the Materials and Methods section. Each point represents the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.





Figure 2. Determination of the optimal LPS concentration for induction of early endotoxin tolerance -- ICR mice were injected i.p. with saline or varying concentrations of E. coli LPS. At 3 days post-injection, mice (5 mice/group) were challenged i.p. with a second injection of E. coli LPS (25  $\mu$ g/mouse). Six hours later, the mice were bled and their sera pooled and assayed for CSF activity as described in the Materials and Methods section. Each point represents the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.



experiments was indeed optimal for the production of serum CSF in response to the particular preparation of *E. coli* K235 LPS used in this study, a 24 h time course was additionally performed. Groups of 5 mice were injected on day 0 with saline or *E. coli* LPS (25  $\mu$ g/mouse) i.p. Three days later, these mice were challenged with 25  $\mu$ g LPS and were bled at various times (0-24 h) thereafter. The results in Figure 3 confirmed the previous findings of Metcalf (1971) that 6 h post-injection of LPS was optimal for detection of serum CSF in control (saline pre-treated) mice. In tolerized mice, i.e., those which had received LPS on day 0, the CSF response was reduced throughout the 24 h time period following the challenge (day 3) injection.

The experiments described thus far utilized CSF production as an indicator of endotoxin responsiveness *in vivo*. To insure that the apparent induction of endotoxin tolerance was not unique or specific for this particular manifestation of endotoxin sensitivity, the serum samples assayed in Figure 3 for CSF activity were also assayed for the presence of interferon (IFN). Previous studies have shown that administration of LPS to endotoxin-responsive animals results in a sharp rise in serum IFN which reaches maximum levels at approximately 2 h post-administration (Youngner and Stinebring, 1965). The results in Figure 4 illustrate that control mice (i.e., those that received saline on day 0) responded normally to LPS with peak IFN levels at 2 h post-injection of LPS. Serum from tolerized mice, however, yielded no detectable levels of IFN throughout the 24 h time period following



Figure 3. 24-hour time course for serum CSF production in non-tolerized and tolerized mice -- ICR mice were injected i.p. with saline or *E. coli* LPS (25  $\mu$ g/mouse). After 3 days, the mice (5 mice/group) were challenged with *E. coli* LPS (25  $\mu$ g/mouse) and bled at the indicated times. Sera from each group were pooled and assayed for CSF activity as described in the Materials and Methods section. Each point represents the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.





Figure 4. 24-hour time course for interferon induction in non-tolerized and tolerized mice — Pooled serum samples, obtained from mice treated as described in the legend of Figure 3, were assayed for the presence of interferon as described in the Materials and Methods section. Results represent the antiviral activity contained in serum pools obtained from 5 mice per treatment group.



challenge.

Further confirmation of the efficacy of this tolerizing regimen was established using LPS-induced lethality and symptoms as a measure of endotoxin sensitivity. Exposure to an initial dose of 25  $\mu$ g LPS/mouse more than doubled the LD<sub>50</sub> (414  $\mu$ g non-tolerized vs. 994  $\mu$ g tolerized) and essentially eliminated overt symptoms of endotoxicity (i.e., diarrhea, ruffled fur, and conjunctival discharge) which are normally observed by 6 h after challenge with a sublethal dose of LPS (25  $\mu$ g/mouse). These data are shown in Table I.

Since one of the characteristics of early endotoxin tolerance is that it is inducible with unrelated LPS preparations (i.e., it is not O-antigen-specific; Greisman and Hornick, 1976), groups of mice were injected with saline or *E. coli* LPS (25  $\mu$ g/mouse) on day 0, but challenged on day 3 with 25  $\mu$ g LPS/mouse of either homologous *E. coli* LPS or heterologous LPS preparations derived from *Pseudomonas aeruginosa*, *Salmonella typhimurium* or *Bacteroides fragilis*. Table II shows that an initial exposure on day 0 to *E. coli* LPS markedly reduced the level of CSF which was induced by challenge with any of the LPS preparations 3 days later.

Failure of the purified polysaccharide derived from *E. coli* K235 LPS to induce early endotoxin tolerance -- Although previous studies had indicated that Lipid A, the biologically active moiety of the LPS molecule, was capable of inducing a state of endotoxin tolerance (Staber, 1980), it had not been

Table I

Effect of early phase endotoxin tolerance on  
clinical endotoxic manifestations

<u>Experimental</u> <u>group</u> <sup>a</sup>	<u>LD<sub>50</sub> (μg)</u> <sup>b</sup>	<u>Symptoms</u> <sup>c</sup>		
		<u>Diarrhea</u>	<u>Ruffled fur</u>	<u>Conjunctival</u> <u>discharge</u>
Non-tolerized	414±55	9/16	13/16	11/16
Tolerized	994±92	0/16	0/16	0/16

<sup>a</sup> Mice were injected i.p. on day 0 with saline (non-tolerized) or *E. coli* K235 LPS (25 μg/mouse; tolerized). Three days later, the mice were challenged with *E. coli* LPS for LD<sub>50</sub> determination and assessment of symptoms as described in the Materials and Methods section.

<sup>b</sup> The LD<sub>50</sub> was calculated by the method of Reed and Muench (1939). Results represent the arithmetic mean ± one standard deviation of two separate LD<sub>50</sub> experiments.

<sup>c</sup> The proportion of mice which clearly exhibited the indicated symptom 6 h after the injection of 25 μg LPS on day 3.

Table II

Effect of initial exposure to *E. coli* LPS  
on CSF induced by subsequent challenge  
with homologous and heterologous LPS preparations<sup>a</sup>

<u>Serum CSF (CFU/ml)</u>				
<u>Treatment</u>	<u>Species of LPS Injected on Day 3</u>			
<u>on day 0</u>	<u><i>E. coli</i></u>	<u><i>P. aeruginosa</i></u>	<u><i>S. typhimurium</i></u>	<u><i>B. fragilis</i></u>
Saline	3,003 ± 450	3,050 ± 361	2,975 ± 136	820 ± 113
<i>E. coli</i>	450 ± 14	380 ± 74	190 ± 70	0
<u>LPS</u>				

<sup>a</sup> Groups of 5 ICR mice were injected i.p. with either *E. coli* LPS (25 µg/mouse) or saline on day 0 and again on day 3 with either homologous *E. coli* LPS or a heterologous LPS preparation (25 µg/mouse) as indicated. Six hours after the day 3 injection, the mice were bled and sera assayed for CSF. The results represent the arithmetic mean ± one standard deviation of duplicate determinations.



demonstrated previously that the polysaccharide moiety was inactive as a tolerogen. This issue was particularly relevant since "purified" polysaccharide derived from LPS using the procedure of Freeman (1942) had been used to induce certain LPS-mediated responses, including the induction of CSF (Urbaschek *et al.*, 1980). In this study, the polysaccharide was prepared by mild acid hydrolysis of the phenol-water extracted *E. coli* K235 LPS and was separated from residual LPS by gel chromatography, as described in the Materials and Methods section. The concentration of polysaccharide was adjusted by total glucose content to be equivalent to the glucose content of 25  $\mu$ g *E. coli* K235 LPS (70 nmoles). When administered to mice on day 0, it was found that the polysaccharide moiety was non-toxic, unable to induce serum CSF, and failed to induce tolerance to LPS as assessed by serum CSF or symptoms of endotoxicity (Table III).

#### EARLY ENDOTOXIN TOLERANCE IS ASSOCIATED WITH ALTERATIONS IN BONE MARROW-DERIVED MACROPHAGE PRECURSOR POOLS

Effect of early endotoxin tolerance on the elicitation of peritoneal exudate macrophages -- Previous studies have indicated that macrophages play a central role in endotoxic reactions through the production of soluble immunoregulatory mediators such as Interleukin 1 and CSF (reviewed in Rosenstreich and Vogel, 1980; Vogel and Mergenhagen, 1982). Since it had been shown that: (1) relative LPS sensitivity

Table III

Effect of purified polysaccharide derived from  
E. coli LPS on induction of CSF or early endotoxin tolerance

<u>Treatment<sup>a</sup></u>		<u>Serum CSF (CFU/ml)<sup>b</sup></u>
<u>Day 0</u>	<u>Day 3</u>	
Saline	Saline	0
Saline	LPS	3,490 $\pm$ 199
LPS	LPS	600 $\pm$ 187
Saline	PS	0
PS	PS	0
PS	LPS	4,100 $\pm$ 891

<sup>a</sup> Groups of 5 ICR mice were injected i.p. on day 0 and day 3 with either saline, E. coli LPS (25  $\mu$ g/mouse), or polysaccharide (PS) derived from E. coli LPS. LPS and PS were equilibrated by total glucose content as described in the Materials and Methods section.

<sup>b</sup> Six hours after the day 3 injection, the mice were bled and the sera assayed for CSF activity. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.

correlated with the differentiation state of the macrophage (Suter *et al.*, 1958; Benacerraf *et al.*, 1959; Moore *et al.*, 1980; Rosenstreich and Vogel, 1980; Vogel *et al.*, 1980) and (2) macrophages from endotoxin-tolerized mice were refractory to LPS stimulation *in vitro* (Dinarelli *et al.*, 1968; Rietschel *et al.*, 1980), we had originally planned to examine the differentiation state of peritoneal exudate macrophages from endotoxin-tolerized mice. When thioglycollate was administered to mice between the initial and challenge LPS injections (Williams *et al.*, 1983), the peritoneal exudate cells recovered from mice which had been injected twice with LPS were strikingly reduced in the proportion of macrophages which were elicited in control mice (Table IV).

Changes in the number of bone marrow-derived macrophage progenitor cells after a single injection of LPS --  
It has been established that mononuclear phagocytes originate from precursors in the bone marrow (Volkman and Gowans, 1965). Therefore, the reduction in peritoneal exudate macrophages in mice injected twice with LPS suggested that such mice might be blockaded in macrophage development. A blockade in development could result in an accumulation of immature precursors in the bone marrow. To test this, an 8 day time course was carried out. Groups of mice were injected with either saline or *E. coli* LPS on day 0, and, on successive days, the pooled bone marrow cells from the femurs of each group were enumerated and plated in an excess of CSF-1. CSF-1 has been shown to be

Table IV  
Effect of LPS administration on  
recovery of thioglycollate-induced  
peritoneal exudate cells

<u>Experimental</u> <u>Group</u> <sup>a</sup>	<u>Percent of White Blood Cells Recovered</u> <sup>b</sup>			
	<u>Macrophages</u>	<u>Neutrophils</u>	<u>Lymphocytes</u>	<u>Other</u>
Saline control (Saline/Saline)	84	10	5	1
Non-tolerized (Saline/LPS)	76	22	1	1
Tolerized (LPS/LPS)	26	72	1	1

---

<sup>a</sup> Mice were treated on day 0 and on day 3 as indicated by the order of treatments in parentheses. Thioglycollate was administered on day 1 and peritoneal exudate cells collected by lavage on day 3, 3 h after the second injection as described by Williams *et al.* (1983).

<sup>b</sup> Cytospin preparations were fixed in methanol and were stained using a modified Wright's stain. Differential counts were performed on 200 cells per slide under oil immersion. Results

represent the arithmetic mean of differential counts derived from two separate experiments.


specific for cells of macrophage lineage and to give rise exclusively to macrophage colonies in culture (Stanley and Guilbert, 1980). Those precursors which respond to CSF-1 to form colonies are referred to as macrophage colony forming units (M-CFU).

A single injection of LPS on day 0 resulted in an initial decrease in the total number of nucleated cells per femur on days 1 and 2 post-injection, followed by a return to normal levels over the next 3 days (Figure 5A). Figure 5B shows that the number of macrophage progenitors (M-CFU), adjusted for the total nucleated cell count from each group, was greatly increased by the third day after LPS injection and returned to normal by day 8. Injection of saline on day 0 produced no significant change in the number of M-CFU per femur over the 8 day period. Additional studies in which mice were injected i.p. with 3 ml/mouse of the sterile inflammatory agent, thioglycollate, and the bone marrow cells cultured for M-CFU on day 3, showed no such increase in the number of macrophage progenitors when compared to saline-injected mice (saline-injected =  $2.1 \times 10^4 \pm 3.9 \times 10^3$  M-CFU/femur vs. thioglycollate-injected =  $2.7 \times 10^4 \pm 4.8 \times 10^3$  M-CFU/femur).

A more primitive population of macrophage progenitors with a higher proliferative potential (HPP) than M-CFU, responds to CSF-1 only in the presence of a synergistic co-factor, referred to as "Synergistic Activity" (Bradley and Hodgson, 1975). The insert in Figure 5B shows that, like the more mature progenitor population (M-CFU), the number of HPP

Figure 5. Effect of a tolerizing injection of LPS on the number of nucleated cells and macrophage precursors in the bone marrow -- ICR mice (5 mice/group) were injected i.p. on day 0 with either saline or *E. coli* LPS (25  $\mu$ g/mouse) and the bone marrow cells from each group were collected and pooled at the indicated times thereafter. Nucleated cell counts for each bone marrow cell suspension were obtained using a Coulter Counter (Figure 5A). Five  $\times 10^4$  cells from each cell suspension were then plated in duplicate in an excess of CSF-1 and the number of M-CFU determined (Figure 5B) as described in the Materials and Methods section. Simultaneously,  $5 \times 10^4$  cells were plated in an excess of CSF-1 plus human spleen conditioned medium (as a source of synergistic activity) for determination of the number of HPP colonies (Figure 5B, insert).





precursors was also increased by day 3 after injection of LPS and the kinetics of their appearance (and disappearance) was similar to the observed alterations in M-CFU numbers.

The number of M-CFU in spleens from tolerized mice was also greatly increased. In the spleens of mice injected 3 days previously with *E.coli* LPS, the number of M-CFU was approximately 14-fold greater than in control mice (saline-injected,  $4 \times 10^3$  M-CFU/spleen; LPS-injected,  $5.7 \times 10^4$  M-CFU/spleen).

Changes in bone marrow cell sizing profiles following a single injection of LPS -- Cell sizing profiles of the various bone marrow cell suspensions were obtained using a Coulter Channelyzer. When control bone marrow cells (day 3, post-saline) were analyzed, a bimodal distribution of cells was observed (Figure 6). Control Peak 1 accounted for 35-40% of the total cells analyzed and consisted of smaller cells (average diameter =  $7.5 \mu$ ) relative to those in Peak 2 (average diameter =  $10 \mu$ ) which accounted for the remaining 55-60% of cells. In contrast, a marked reduction in the relative number of bone marrow cells in Peak 1 (20% of total) occurred in tolerized mice (day 3, post-LPS) and there was a compensatory increase in the number of cells within Peak 2 (80%). In addition, the Peak 2 cells from tolerized mice were larger than those in the Control Peak 2 (average diameter =  $11.4 \mu$ ; as indicated by the shift to the right on the sizing profile). Figure 7 indicates that the acquisition and loss of this cell

Figure 6. Effect of a tolerizing injection of LPS on bone marrow cell sizing profiles -- ICR mice (5 mice/group) were injected i.p. on day 0 with either saline or E. coli LPS (25  $\mu$ g/mouse). At 3 days post-injection, the mice were re-injected with saline or E. coli LPS (25  $\mu$ g/mouse) and sacrificed immediately. Bone marrow cells were then pooled from each group and cell sizing profiles obtained using a Coulter Channelyzer.





Figure 7. Cell sizing profiles of bone marrow cells obtained at various times after LPS injection -- ICR mice (5 mice/group) were injected i.p. with *E. coli* LPS (25  $\mu$ g/mouse) and sacrificed at the indicated times after injection. Cell sizing profiles of bone marrow cells pooled from each group were obtained using a Coulter Channelyzer. The arrow indicates the initial position of Peak 2.



sizing profile correlated temporally with the acquisition, maintenance, and loss of tolerance (see Figure 1).

#### Density gradient separation of mouse bone marrow cells

— To determine whether a relationship existed between the cell sizing profile in tolerized mice (day 3, post-LPS) and the increased number of M-CFU also seen at this time, Peak 1 was separated from Peak 2 by density gradient sedimentation and the numbers of M-CFU in individual fractions determined (Figure 8). All of the M-CFU activity was restricted to the dense fractions (i.e., Peak 2) in both saline- and LPS-injected mice. Based on two separate experiments, the total number of M-CFU (obtained by adding the M-CFU values determined for individual density gradient fractions) from tolerized mice was >2.5 times greater than obtained from control mice. To verify the relative positions of Peak 1 and Peak 2 after density gradient sedimentation, pooled fractions were re-analyzed by Coulter Channelyzer (Figure 9). Thus, the results of Figures 8 and 9 indicate that all of the M-CFU activity was found in Peak 2, and that the increase observed in unfractionated, tolerized bone marrow cells was reflected in the separated fractions. In addition, the distribution of HPP precursors was also measured in individual density gradient fractions and also correlated positionally with Peak 2 as well as with M-CFU activity (Figure 8).

When differential counts of cytospin preparations of the pooled, density gradient-separated Peak 2 cells were



Figure 8. Density gradient separation and measurement of M-CFU and HPP activity -- ICR mice (5 mice/group) were injected i.p. on day 0 with either saline or *E. coli* LPS (25  $\mu$ g/mouse). On day 3, bone marrow cells were collected and  $1 \times 10^7$  cells from each group were separated by density gradient sedimentation as described in the Materials and Methods section. Fractions (3 ml/fraction) were collected from the bottom of the gradient after 3.5 h. Cells from each fraction were enumerated and then cultured in the presence of CSF-1 or CSF-1 plus human spleen conditioned medium (as a source of synergistic activity) to determine the numbers of M-CFU and HPP, respectively. The first fractions collected had to be pooled in order to obtain adequate numbers of cells for culture. M-CFU and HPP determinations were carried out in duplicate as described in the Materials and Methods section.





Figure 9. Cell sizing profiles of pooled density gradient-separated bone marrow cells -- Cells from each fraction (see Figure 8) were sized using a Coulter Channelyzer and then pooled according to profile similarities with unseparated Peak 1 vs. Peak 2. Cell sizing profiles were then obtained on the pooled fractions. The arrow indicates the position of control Peak 2. Cells from the pooled fractions were enumerated and cultured in the presence of CSF-1 and the number of M-CFU determined in duplicate as described in the Materials and Methods section.



performed (Table V), cells derived from tolerized mice were enriched for the number of large mononuclear cell types. These latter cells contained a large nucleus (nuclear:cytoplasmic ratio >1) and the cytoplasm was strongly basophilic, suggesting the monoblast-promonocyte stage of macrophage development (Sumner *et al.*, 1972; Goud *et al.*, 1975).

Changes in the number of M-CFU after a second injection of LPS -- Based on the observation that a single injection of *E. coli* LPS resulted in profound changes in the numbers of bone marrow-derived macrophage progenitors which correlated temporally with maximum tolerance induction, the effect of a second (challenge) injection of LPS on M-CFU levels was also investigated. Groups of mice were injected with either saline or LPS on day 0 and again on day 3. After the second injection, bone marrow cells from each group were collected at 0, 3, and 24 h post-injection. Figure 10 demonstrates that in mice which received LPS on day 3 for the first time, a marked decrease was observed in both the number of nucleated cells (data not shown; refer to Figure 5A) and M-CFU within 24 h post-LPS (refer back to Figure 5B). In mice which received LPS for a second time on day 3, only a slight decrease in the number of nucleated cells was observed (from  $9.8 \times 10^6$  to  $7.5 \times 10^6$  cells/femur at 24 h); however, the already elevated level of M-CFU/femur was maintained (Figure 10).

Effect of repeated injections of *E. coli* LPS -- Since

Table V

Differential counts of cytopsin preparations of density  
gradient - separated Peak 2 cells<sup>a</sup>

	<u>Treatment Group</u>	
	<u>Control</u>	<u>Tolerized</u>
Polymorphonuclear cells	48.5% <sup>b</sup>	16.0%
Small mononuclear cells (10-15 $\mu$ diameter)	50.5%	43.3%
Large mononuclear cells (15-21 $\mu$ diameter)	1.0%	41.0%


---

<sup>a</sup>Peak 2 bone marrow cells were isolated and pooled by density gradient sedimentation on day 3 after the injection of saline (control) or 25  $\mu$ g/mouse *E. coli* LPS (tolerized) on day 0.

<sup>b</sup>Cytopsin preparations of pooled Peak 2 cells were fixed in methanol and stained using a modified Wright's stain. Differential counts (200 cells per slide) were obtained under oil immersion.

Figure 10. Effect of a second injection of *E. coli* LPS on the number of bone marrow-derived M-CFU -- ICR mice (5 mice/group) were injected i.p. on day 0 with either saline or *E. coli* LPS (25  $\mu$ g/mouse). On day 3, the mice injected with saline on day 0 were injected again with either saline (control) or LPS (non-tolerized) and those injected initially with LPS were re-injected with LPS (tolerized). At 0, 3 and 24 h after the day 3 injection, the mice were sacrificed and the number of M-CFU determined in duplicate as described in Materials and Methods section.





early endotoxin tolerance was found to be optimal 3 days after initial exposure to LPS and the increased number of bone marrow M-CFU, also observed on day 3, was maintained for at least 24 h following a second injection of LPS (Figure 10), the effect of multiple LPS injections was investigated next. Groups of mice were injected with either saline or LPS one time (on day 0 only), twice (on days 0 and 3), or three times (on days 0, 3, and 6). To assess the effect of repeated injections of LPS on tolerance, mice were challenged with 25  $\mu$ g *E. coli* K235 LPS 3 days after their last injection, and their serum collected 6 h post-challenge for measurement of CSF activity. The results in Figure 11A indicate that, with respect to serum CSF, endotoxin tolerance was maintained at the same level, regardless of whether the mice received one, two, or three "tolerizing" injections. Control mice injected with saline one, two, or three times responded normally to a single challenge injection of LPS to produce high levels of serum CSF.

In order to assess the effect of repeated LPS injections on the number of bone marrow M-CFU, mice injected with either saline or LPS were sacrificed 3 days after their last "tolerizing" injection and their bone marrow cells cultured in an excess of CSF-1. Figure 11B demonstrates that mice which received one previous injection of LPS responded with a dramatic increase in M-CFU 3 days later (compare with Figure 5B). However, with repeated injections of LPS, the number of M-CFU was diminished so that after 3 injections, M-CFU numbers were equivalent to saline-injected controls.

Figure 11A. Effect of repeated injections of E. coli LPS on the level of serum CSF following LPS challenge -- ICR mice (5 mice/group) were injected once, twice, or three times at three day intervals with saline or E. coli LPS (25  $\mu$ g/mouse) and were challenged with 25  $\mu$ g E. coli LPS 3 days after the last injection. Six hours later, the mice were bled, the sera from each group pooled and assayed for CSF activity. The data represent the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.





Figure 11B. Effect of repeated injections of E. coli LPS on the number of bone marrow-derived M-CFU -- ICR mice (5 mice/group) were injected once, twice, or three times at three day intervals with saline or E. coli LPS (25  $\mu$ g/mouse). Mice were sacrificed 3 days after their last injection and bone marrow cells from each group pooled, enumerated, and the number of M-CFU determined as described in the Materials and Methods section. The data represent the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.



Cell sizing profiles of the various bone marrow suspensions were also compared using a Coulter Channelyzer. As can be seen in Figure 11C, one injection of LPS induced a marked reduction in the relative number of cells in Peak 1 (saline-injected = 40% of total cells; LPS-injected = 20% of total cells), and, a compensatory increase in the number of cells within Peak 2 (saline-injected = 60% of total cells; LPS-injected = 80% of total cells). This was accompanied by an increase in size in Peak 2. Repeated injections of LPS resulted in a marked decline in the average size of cells in Peak 2 (see Figure 6).

Effect of repeated injections of *Pseudomonas aeruginosa* LPS on serum CSF induction by *E. coli* K235 LPS -- Because early phase endotoxin tolerance is not O-antigen specific (Greisman and Hornick, 1976; see Table II), the previous series of experiments was modified such that groups of mice were injected once, twice, or three times with saline or *Ps. aeruginosa* LPS (25 µg/mouse). Three days after the last injection, groups of mice were either challenged with *E. coli* K235 LPS (for serum CSF) or sacrificed and their bone marrow cells analyzed for alterations in sizing profiles. Figure 12A illustrates that heterologous tolerance for *E. coli* LPS was induced by multiple injections of *Ps. aeruginosa* LPS, but on the basis of percent suppression of the control response, appeared to be somewhat less efficacious (Table VI). The bone marrow profiles in Figure 12B indicate that: (1) the "shift" in



Figure 11C. Effect of repeated injections of E. coli LPS on bone marrow cell sizing profiles -- ICR mice (5 mice/group) were repeatedly injected once, twice, or three times at 3 day intervals with saline or E. coli LPS (25  $\mu$ g/mouse). Three days following the last injection, the mice were sacrificed, bone marrow cells obtained, and cell sizing profiles determined using a Coulter Channelyzer. The arrow indicates the relative position of Peak 2 bone marrow cells from control ICR mice.




Figure 12A. Effect of repeated injections of *Pseudomonas aeruginosa* LPS on serum CSE induction by *E. coli* LPS --- ICR mice (5 mice/group) were injected with saline or *Pseudomonas aeruginosa* LPS (25  $\mu$ g/mouse) once, twice, or three times at three day intervals and were challenged with *E. coli* LPS (25  $\mu$ g/mouse) 3 days after the last injection. Six hours later, the mice were bled and the sera assayed for CSE activity. Each point represents the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.




Table VI

Percent suppression of control serum CSF response  
in mice tolerized with homologous or heterologous  
preparations of LPS<sup>a</sup>

Treatment Group <sup>b</sup>	No. of LPS Injections Prior to Challenge with <i>E. coli</i> LPS		
	1	2	3
Homologous tolerance system ( <i>E. coli</i> LPS)	80 <sup>c</sup>	75	82
Heterologous tolerance system ( <i>Ps. aeruginosa</i> LPS)	80	60	60

---

<sup>a</sup> This table is a summary of the data presented in Figures 12A (homologous endotoxin tolerance) and 13A (heterologous endotoxin tolerance).


<sup>b</sup> Mice were injected once, twice, or three times at 3 day intervals with saline, *E. coli* LPS, or *Ps. aeruginosa* LPS. Three days after the last injection, all mice were challenged with *E. coli* LPS.

<sup>c</sup> The data represent the percent suppression of the control CSF

response (saline-injected 1 to 3 times followed by challenge with E. coli LPS).

Figure 12B. Effect of repeated injections of Pseudomonas aeruginosa LPS on bone marrow cell sizing profiles -- ICR mice (5 mice/group) were injected with saline or Ps. aeruginosa LPS once, twice, or three times at three day intervals. Three days following the last injection, the mice were sacrificed, the bone marrow cells obtained, and cell sizing profiles determined using a Coulter Channelyzer. The arrow indicates the relative position of Peak 2 bone marrow cells from control (saline-injected) ICR mice.





Peak 2 seen three days after one injection of *E. coli* LPS was also seen after a single injection of *Ps. aeruginosa* LPS, and (2) the reduction in the average size of cells in Peak 2 observed after repeated injections of *E. coli* LPS was also observed in mice injected repeatedly with *Ps. aeruginosa* LPS (compare Figure 12B with Figure 11C).

#### INDUCTION OF EARLY ENDOTOXIN TOLERANCE IN OTHER MURINE MODELS

In order to gain a better understanding of the cellular mechanisms which underlie early phase endotoxin tolerance, several additional murine models were studied with respect to serum CSF induction, bone marrow M-CFU, or bone marrow cell sizing profiles after prior exposure to LPS.

Effect of tolerizing regimen on inbred mice which differ in their inherited sensitivity to LPS -- C3H/HeJ mice bear a single autosomal mutation, *Lps*<sup>d</sup> (Watson et al., 1978), which renders this strain highly refractory to the effects of LPS both *in vivo* and *in vitro* (reviewed by Morrison and Ryan, 1979). Use of this naturally LPS-hyporesponsive strain in conjunction with syngeneic, fully LPS-responsive strains (*Lps*<sup>a</sup>), has provided evidence that macrophages figure centrally in the induction of LPS-induced pathophysiologic changes associated with endotoxicity (reviewed by Rosenstreich and Vogel, 1980). We next sought to determine if any of these

changes were present in the LPS-hyporesponsive C3H/HeJ strain. C3H/HeJ (LPS-hyporesponsive) and syngeneic, LPS-responsive C3H/OuJ mice were subjected to the tolerizing regimen which had been established for ICR mice. Each mouse strain received either saline (control) or *E. coli* K235 LPS (25  $\mu$ g/mouse) i.p. on day 0. On day 3, mice were challenged with *E. coli* LPS (25  $\mu$ g/mouse), bled 6 h later, and sera assayed for CSF activity. The results in Table VII show that C3H/OuJ mice responded to LPS-challenge similarly to outbred ICR mice, i.e., a dramatic increase in serum CSF from control (saline-pretreated) mice and a mitigated CSF response in tolerized mice (i.e., those pretreated with LPS). In contrast, C3H/HeJ mice did not respond with detectable levels of serum CSF after either treatment.

Bone marrow cell sizing profiles of LPS-responsive (C3H/OuJ) and LPS-hyporesponsive (C3H/HeJ) mice were compared 3 days after injection of saline or LPS (Figure 13). Cell profiles from LPS-responsive C3H/OuJ mice, injected on day 0 with 25  $\mu$ g LPS, showed a cell sizing profile similar to that seen in LPS-injected, outbred ICR mice, i.e., a dramatic increase in the average size and number of cells in Peak 2. In contrast, the cell sizing profile from LPS-hyporesponsive C3H/HeJ mice was not altered. One mg LPS per mouse was required to cause any significant alteration in the cell profile. Specifically, in response to saline, 25  $\mu$ g or 100  $\mu$ g LPS, Peak 1 comprised approximately 40% of the total cell population. In response to 1 mg LPS, Peak 1 comprised 33% of

Table VII  
LPS-induced serum CSF response in  
LPS-responsive (C3H/OuJ) and  
LPS-hyporesponsive (C3H/HeJ) mice


Experimental group	Treatment <sup>a</sup>		CSF (CFU/ml) <sup>b</sup>
	Day 0	Day 3	
C3H/OuJ (Lps <sup>n</sup> )	Saline	Saline	0
	Saline	LPS	7,000 ± 250
	LPS	LPS	1,300 ± 110
C3H/HeJ (Lps <sup>d</sup> )	Saline	Saline	0
	Saline	LPS	0
	LPS	LPS	0

<sup>a</sup> Groups of 5 C3H/OuJ or C3H/HeJ mice were injected i.p. with either saline or *E. coli* LPS (25 µg/mouse) on day 0. Three days later, mice were injected with saline or challenged with *E. coli* LPS (25 µg/mouse).

<sup>b</sup> CSF levels were determined on pooled serum samples collected 6 h after the injections on day 3. Results represent the arithmetic mean ± one standard deviation of duplicate determinations.



Figure 13. Effect of the tolerizing regimen on the bone marrow cell sizing profile of inbred LPS-responsive and LPS-hyporesponsive mice -- LPS-responsive (C3H/OuJ) and LPS-hyporesponsive (C3H/HeJ) mice (5 mice/group) were injected i.p. on day 0 with either saline or *E. coli* LPS (25 µg/mouse). At 3 days post-injection, bone marrow cells were pooled and sizing profiles obtained using a Coulter Channelyzer. Bone marrow cells obtained 3 days post-injection were also plated in an excess of CSF-1 for determination of the numbers of M-CFU as described in the Materials and Methods section. Based on two separate experiments, the number of M-CFU/ $10^5$  nucleated bone marrow cells were as follows: saline-treated, C3H/OuJ =  $101 \pm 11.9$ ; LPS-treated, C3H/OuJ =  $233 \pm 9.8$ ; saline-treated, C3H/HeJ =  $92.6 \pm 14$ ; LPS-treated, C3H/HeJ =  $102 \pm 2.8$ .



the total cell population with a compensatory increase in the number of cells in Peak 2 (67%). The number of M-CFU was also increased in bone marrow cells derived from C3H/0uJ mice exposed on day 0 to LPS. No such increase was observed in bone marrow cells derived from endotoxin-treated C3H/HeJ mice (indicated in the figure legend, Figure 13).

Induction of early phase endotoxin tolerance in congenitally athymic, T-cell deficient (nude) mice -- Since the initial description of a hairless, mutant (nude) mouse by Flanagan (1966) and further observations by Pantelouris (1968) which showed that such mice were athymic, T cell-deficient, nude mice have been used to study the role of T cells in antibody- and cell-mediated immune responses (reviewed by Kindred, 1981). Homozygous expression of the "nude" allele (nu/nu) results in congenitally athymic mice that possess extremely low levels of functional T cells. Several recent reports suggest the existence of LPS-responsive T cells (Vogel et al., 1983; Mita et al., 1982; McGhee et al., 1979; Koenig et al., 1977; Scheid et al., 1973). Therefore, to determine if T cells were involved in early endotoxin tolerance induction, nude mice were studied.

BALB/c athymic nude (nu/nu) mice and their euthymic (nu/+) littermates were injected with either saline or E. coli K235 LPS (25  $\mu$ g/mouse) i.p. on day 0 and challenged 3 days later with E. coli LPS (25  $\mu$ g/mouse). Mice were bled 6 h following challenge and sera tested for CSF activity. When

athymic and euthymic mice were injected with saline on day 0, both responded to an LPS challenge on day 3 with the production of serum CSF (Figure 14). Exposure to LPS on day 0 tolerized both athymic and euthymic mice as evidenced by a greatly reduced production of serum CSF when challenged on day 3 with LPS.

Recent studies have suggested that certain athymic mouse strains contain substantial numbers of T cells (Ikehara *et al.*, 1984; Habu and Okumura, 1984). The spleens of the nude mice used in this study were analyzed for the presence of a T-cell marker, Thy 1.2, by analysis with a fluorescence activated cell sorter (FACS). Single cell spleen cell suspensions from individual BALB/c (nu/nu) and (nu/+) mice were prepared. Aliquots of each suspension were treated with fluoresceinated anti-mouse IgM ( $\mu$  heavy chain specific) to detect B cells, anti-Thy 1.2 (to detect T cells), or control antibody, as described in the Materials and Methods section, and fluorescence analysis was carried out. The BALB/c (nu/nu) mice used in this study were very deficient in the number of cells which stained specifically for Thy 1.2 (3%) when compared with spleen cells derived from the euthymic controls (24.4%) (Table VIII). The percentage of Thy 1.2 positive cells also differed with respect to median fluorescence intensity (MFI). Thus, the few spleen cells from athymic mice which stained positively for Thy 1.2 expressed far less of this surface antigen than spleen cells from euthymic mice. The percentage of spleen cells expressing  $\mu$  was as expected higher in the



Figure 14. Effect of the tolerizing regimen on LPS-induced serum CSF response in BALB/c euthymic (nu/+) and BALB/c athymic (nu/nu) mice -- BALB/c euthymic and athymic mice (5 mice/group), were injected on day 0 with either saline or *E. coli* LPS (25  $\mu$ g/mouse) and challenged 3 days later with 25  $\mu$ g *E. coli* LPS. Six hours later, serum was collected and assayed for CSF activity as described in the Materials and Methods section. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.




Table VIII

FACS analysis of Thy 1.2 positive and  
IgM positive cells obtained from BALB/c euthymic (nu/+) or  
BALB/c athymic (nu/nu) mice

Spleen cell source <sup>a</sup>	Percent Positive Cells (MFI) <sup>b</sup>	
	Thy 1.2	IgM
BALB/c euthymic (nu/+)	24.4±1.5 (473±28)	58.2±2.8 (352±36)
BALB/c athymic (nu/nu)	3.0±0.7 (290±34)	71.0±4.6 (392±5.4)

<sup>a</sup> Individual spleen cell suspensions from 5 athymic and 5 euthymic BALB/c mice were treated with fluoresceinated antibody as indicated in the Materials and Methods section.

<sup>b</sup> Fluorescence analysis was carried out on each sample using a fluorescence-activated cell sorter, and the percentage of cells which stained with the indicated antibody and median fluorescence intensity (MFI) determined. Results, expressed as percent positive cells, represent the arithmetic mean ± one standard deviation of measurements made on individual spleen

---

cell suspensions.

athymic mouse strain due to the anticipated T-cell deficiency.

Induction of early endotoxin tolerance in the C3.CBA/N (xid) mouse strain -- CBA/N mice possess a defective X-linked gene, xid, which interferes with the development of cells that express the Lyb'5 surface antigen (Ahmed et al., 1977). These mice are unable to respond to a number of B cell mitogens, including purified polysaccharides and LPS (Amsbaugh et al., 1974; Scher, 1982). Although spleen cells from CBA/N mice are deficient with respect to LPS-induced mitogenesis (Glode and Rosenstreich, 1976), these mice are fully responsive to the toxic effects of LPS and possess macrophages which respond normally to LPS in vitro to produce Interleukin 1 (Rosenstreich et al., 1978). Zaldivar and Scher (1979) have compared immune-defective (xid) F<sub>1</sub> male mice with immunologically normal F<sub>1</sub> female mice derived from the crosses of the CBA/N strain with DBA/2 mice. Their results indicate that although the immune-defective male mice were unable to make a specific immune response to E. coli LPS, this did not influence either their natural resistance to LPS lethal challenge or the development of late phase tolerance (antibody-mediated) to LPS after pretreatment with a sublethal amount of LPS and administration of LPS 10 days later.

In 1983, Mond et al. showed that spleen cells from the C3.CBA/N mice (which possess the xid gene defect on a fully LPS-responsive C3H/HeN background) fail to respond in vitro to B-cell mitogens, including LPS. In the following series of



experiments, C3.CBA/N mice were utilized to determine whether the population of LPS-responsive B cells which is deficient in these mice were involved in the induction of early endotoxin tolerance. Consequently, C3.CBA/N female mice, homozygous for the xid defect (xid/xid), were age-matched with C3H/HeN female mice and were subjected to the tolerizing regimen. Mice from each strain were injected with either saline or *E. coli* K235 LPS on day 0 and either challenged 3 days later with LPS and bled to obtain serum for assessment of CSF activity, or sacrificed on day 3 to obtain bone marrow cells for culture of M-CFU and cell sizing profiles. The xid defect of C3.CBA/N mice had no effect on the induction of serum CSF after LPS challenge of mice injected on day 0 with saline (Figure 15). Moreover, pre-exposure on day 0 to LPS resulted in early endotoxin tolerance as assessed by a reduction in serum CSF following LPS challenge.

Bone marrow cell sizing profiles from control (saline-injected) C3.CBA/N and C3H/HeN mice revealed a characteristic bimodal distribution of cells. The pattern was altered in both the normal and defective mice by exposure to LPS 3 days earlier. Both strains also responded to prior LPS exposure with an increase (approximately 3-fold) in the number of bone marrow-derived macrophage progenitor cells (Table IX).

Induction of early endotoxin tolerance in splenectomized ICR mice -- The LPS-tolerance system in ICR mice was recently established by Williams et al. (1983) to

Figure 15. Effect of the tolerizing regimen on LPS-induced serum CSF response in C3H/HeN and C3.CBA/N (xid) mice --

C3H/HeN and C3.CBA/N mice (5 mice/group) were injected on day 0 with either saline or *E. coli* LPS (25 µg/mouse) and challenged 3 days later with 25 µg *E. coli* LPS. Six hours later, serum was collected and assayed for CSF activity as described in the Materials and Methods section. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.






Table IX

LPS-induced alterations in bone marrow cell sizing profiles  
and M-CFU numbers in C3H/HeN and C3.CBA/N (xid) mice<sup>a</sup>

Mouse Strain	Treatment on day 0	M-CFU/femur <sup>b</sup>	% of cells in Peak 2 <sup>c</sup>	Diameter of Peak- 2 cells ( $\mu$ ) <sup>c</sup>
C3H/HeN	Saline	13,260 $\pm$ 1,441	59	10
	LPS	26,345 $\pm$ 233	77	11.4
C3.CBA/N	Saline	11,050 $\pm$ 919	64	10
(xid)	LPS	29,325 $\pm$ 487	84	11.4

<sup>a</sup> Mice (5 mice/group) were injected i.p. with saline or *E. coli* LPS (25  $\mu$ g/mouse) on day 0 and sacrificed on day 3. Bone marrow cells from each group were then pooled and sizing profiles obtained using a Coulter Channelyzer.


<sup>b</sup> Five  $\times 10^4$  pooled bone marrow cells from each group were plated in an excess of CSF-1 and the number of M-CFU per femur determined as described in the Materials and Methods section.

<sup>c</sup> Calculated from integration data which was obtained using the Coulter Channelyzer which was calibrated according to the manufacturer's instructions.

identify those cells which produce CSF in response to LPS. In that study, it was demonstrated that early endotoxin tolerance could be reversed by injection of tolerized mice with spleen cells or a mixture of splenic lymphocytes (macrophage depleted) plus thioglycollate-elicited peritoneal macrophages from control mice 24 h prior to LPS challenge. The authors, therefore, suggested that spleen cells contribute significantly in the production of circulating CSF. To assess further the importance of the spleen and its resident cells in the induction of early phase endotoxin tolerance, a different approach was employed. ICR mice were divided into three main experimental groups, i.e., splenectomized, sham-splenectomized, and untreated (no surgery). Mice which had surgery were allowed to recover completely and were then injected on day 0 with either saline or *E. coli* K235 LPS. Three days later, the respective groups were either challenged with LPS and bled 6 h later (for measurement of serum CSF activity), or sacrificed without challenge for the collection of bone marrow cells (for determination of the numbers of M-CFU colonies and cell sizing profiles). Results in Figure 16A illustrate that: (1) high levels of LPS-induced serum CSF were found in all three experimental groups, regardless of treatment and, (2) splenectomized mice had a reduced capacity to generate CSF in response to LPS challenge (i.e., they could be tolerized to the same extent as controls).

The effect of the tolerizing regimen on bone marrow cell sizing profiles and M-CFU numbers was also assessed. Bone

Figure 16A. Effect of the tolerizing regimen on LPS-induced serum CSF in control and splenectomized mice -- Groups of 5 ICR mice from each experimental group, i.e., splenectomized, sham-splenectomized, and untreated (no surgery), were injected on day 0 with either saline or *E. coli* LPS (25  $\mu$ g/mouse) and challenged 3 days later with 25  $\mu$ g *E. coli* LPS. Six hours later, serum was collected and assayed for CSF activity as described in the Materials and Methods section. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.






marrow cell sizing profiles from splenectomized and sham-splenectomized mice were obtained 3 days after injection of saline or LPS. The bone marrow profiles shown in Figure 16B illustrate that removal of spleens has little or no effect on the LPS-induced bone marrow cell sizing profile, i.e., both splenectomized and sham-splenectomized bone marrow cells exhibited a reduction in Peak 1 and increase in cell size and number in Peak 2 following injection with LPS when compared to the profiles obtained from saline-treated mice. The number of bone marrow M-CFU was also shown to be increased in both groups three days following administration of LPS (indicated in figure legend, Figure 16B).

#### INFECTION OF CONTROL AND LPS-TOLERIZED ICR MICE WITH A GRAM NEGATIVE ORGANISM

Bacterial endotoxins affect the pathogenicity of a wide variety of organisms including bacteria, fungi, parasites, and viruses (reviewed by Cluff, 1971). Endotoxins induce resistance to infection over approximately the same time interval as they induce LPS-hyporesponsiveness, (Beeson, 1947a; Beeson, 1947b). Endotoxin-induced resistance to infection occurs independently of the generation of O-specific antibodies (Milner, 1973). However, the correlation of endotoxin tolerance with resistance to infection varies enormously. This variation has been attributed to differences in the dose of

Figure 16B. Bone marrow cell sizing profiles from splenectomized and sham-splenectomized ICR mice following LPS administration -- On day 0, splenectomized or sham-splenectomized ICR mice (5 mice/group) were injected with saline or *E. coli* LPS (25 µg/mouse). Three days later the mice were sacrificed, the bone marrow cells obtained, and the cell sizing profiles determined using a Coulter Channelyzer. The arrow indicates the relative position of Peak 2 bone marrow cells from control (saline-injected) ICR mice. The number of M-CFU/10<sup>5</sup> nucleated bone marrow cells were as follows: saline-treated, splenectomized = 110 ± 3; LPS-treated, splenectomized = 192 ± 9; saline-treated, sham-splenectomized = 98 ± 4; LPS-treated, sham-splenectomized = 234 ± 21.



endotoxin, the route of administration, the time interval prior to infectious challenge, and the pathogenic course of the agent.

To assess the potential of the early endotoxin tolerance regimen established in this study to protect against a Gram negative infection, it was deemed important to choose an infectious model which coincided temporally with the transiency of the tolerance system (see Figure 1). A well-defined model for Ps. aeruginosa infection was established by Stieritz and Holder (1975) and modified by Pavlovskis et al. (1977). With this system, mice are first administered a third-degree burn and then are immediately infected subcutaneously with Ps. aeruginosa at the burn site. Deaths are recorded for a seven day period.

Groups of 5 or 10 mice were injected on day 0 with either saline or 25  $\mu$ g E. coli K235 LPS i.p. Three days later, the mice were burned and injected subcutaneously at the burn site with varying concentrations of Ps. aeruginosa. The results shown in Table X indicate that mice tolerized with E. coli LPS exhibit a higher degree of resistance to infection (compared with control saline-injected mice), particularly at the higher doses ( $3 \times 10^7$  -  $3 \times 10^8$  bacteria/mouse). This resistance, as assessed by mean time to death (MTD), however, was transient, waned within 2 days post-challenge (day 5 post-LPS), and was not observed with lower challenge inocula. There was no statistical difference in the LD<sub>50</sub>'s calculated from control and tolerized experimental groups.



Table X  
Infection of control and tolerized ICR mice  
with *Pseudomonas aeruginosa*

<u>Treatment</u> <u>Group<sup>a</sup></u>	<u>Inoculum</u>	<u>Percent Cumulative Deaths<sup>b</sup></u> <u>Day post-bacterial challenge</u>			
		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>
Control	$3 \times 10^8$	60	100	100	100
Tolerized	$3 \times 10^8$	27 <sup>c</sup>	87 <sup>c</sup>	93	93
Control	$3 \times 10^7$	53	100	100	100
Tolerized	$3 \times 10^7$	0 <sup>c</sup>	87 <sup>c</sup>	100	100
Control	$3 \times 10^6$	0	47	67	73
Tolerized	$3 \times 10^6$	0	60	62	62
Control	$3 \times 10^5$	0	20	33	40
Tolerized	$3 \times 10^5$	0	20	40	40
Control	$3 \times 10^4$	0	0	0	0
Tolerized	$3 \times 10^4$	0	0	7	7
Control	$3 \times 10^3$	0	0	0	0
Tolerized	$3 \times 10^3$	0	0	7	7

<sup>a</sup> ICR mice were treated on day 0 with either saline or *E. coli* LPS (25 µg/mouse). On day 3, mice were injected subcutaneously with *Pseudomonas aeruginosa* at a burn site with the indicated number of bacteria (inoculum).

<sup>b</sup> The results are presented as the cumulative percentage of deaths for each day after bacterial injection and represent the combined data from two separate experiments in which a total of 15 mice per experimental group were treated. The calculated LD<sub>50</sub> (based on two separate experiments) for control and tolerized mice were  $8.8 \times 10^5$  and  $7.6 \times 10^5$  bacteria, respectively.

<sup>c</sup>  $p < .05$  by a one-tailed, Kolmogorov-Smirnov two-sample test (Siegel, 1956).

INDUCTION OF EARLY PHASE ENDOTOXIN TOLERANCE BY A DETOXIFIED  
LIPID A DERIVATIVE, MONOPHOSPHORYL LIPID A (MPL)

Although endotoxin has been shown to induce many of the harmful manifestations seen in patients with Gram negative sepsis, some of the effects of endotoxin are beneficial (reviewed by Nowotny, 1983). However, therapeutic approaches which use endotoxin to induce beneficial effects have been limited because man is very sensitive to the toxic effects of endotoxin. Investigators have explored the possibility of using chemical modification techniques to reduce the toxicity and pyrogenicity of endotoxin while retaining beneficial effects such as adjuvanticity (Nowotny, 1963; Johnson *et al.*, 1964; Ribi *et al.*, 1979). Takayama *et al.* (1984) have recently described a detoxified Lipid A derivative, monophosphoryl Lipid A (MPL). Therefore, in this final series of experiments, we have studied the capacity of the nontoxic, monophosphoryl Lipid A derivative to induce early endotoxin tolerance.

Induction of serum CSF by MPL -- Injection of *E. coli* K235 LPS into mice was followed by a rapid rise of serum CSF which reached a maximum level at approximately 6 h post-injection. To test whether the non-toxic Lipid A derivative, MPL, was also able to induce this manifestation of endotoxin responsiveness, groups of 5 mice were injected

intravenously with varying doses of MPL. At 6 h following injection, the mice were bled and the serum subsequently tested for the presence of CSF. The results in Figure 17A show that serum CSF was induced over a wide dose range (1.0  $\mu$ g - 100  $\mu$ g/mouse) and was induced optimally with 50  $\mu$ g MPL/mouse. Additionally, MPL induced a similar (although somewhat reduced) dose-dependent response in mice injected intraperitoneally. These data are shown in Table XI.

Induction of early endotoxin tolerance by MPL to challenge with intact *E. coli* K235 LPS -- The findings of Williams *et al.* (1983) and those presented in Figure 1 indicated that early endotoxin tolerance was optimal 3-4 days after initial exposure to either a homologous or heterologous preparation of LPS. To test whether an initial exposure to MPL would also render animals refractory to LPS, we injected groups of mice with varying concentrations of MPL, and 3 days later challenged these same mice with *E. coli* LPS (25  $\mu$ g/mouse). Six hours after challenge, blood was collected and the serum assayed for CSF activity. As can be seen in Figure 17B, increasing the dose of MPL given on day 0 from 1  $\mu$ g to 100  $\mu$ g reduced significantly the LPS-induced serum CSF response upon challenge with 25  $\mu$ g *E. coli* LPS on day 3. This degree of LPS-hyporesponsiveness was equivalent to that seen when 25  $\mu$ g *E. coli* LPS was used as the tolerogen (Figure 17B).

Another indicator of LPS responsiveness *in vivo* is the induction of serum interferon (IFN) which usually peaks 2-3 h following intravenous administration of intact LPS or Lipid A

Figure 17A. MPL-induction of serum CSF -- ICR mice (5 mice/group) were injected with either saline, *E. coli* LPS (25  $\mu$ g/mouse), or MPL (1 - 100  $\mu$ g/mouse) i.v. Six hours later, the mice were bled, sera collected, pooled, and assayed for CSF activity as described in the Materials and Methods section. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate samples of serum pools from three separate experiments in which 5 mice per treatment per experiment were pooled.




Table XI


Induction of serum CSF in ICR mice injected  
intravenously or intraperitoneally with MPL<sup>a</sup>

Concentration of MPL injected ( $\mu$ g/mouse)	<u>Route of MPL Administration</u>	
	<u>Intravenous</u>	<u>Intraperitoneal</u>
	<u>Serum CSF (CFU/ml)</u>	
0	0	0
1	560 $\pm$ 37	NT
10	2,170 $\pm$ 186	640 $\pm$ 130
25	2,900 $\pm$ 365	1,900 $\pm$ 254
50	3,500 $\pm$ 174	2,560 $\pm$ 488
100	2,400 $\pm$ 218	1,210 $\pm$ 285

<sup>a</sup>ICR mice (5 mice/group) were injected with either saline or MPL (1-100  $\mu$ g) i.v. or i.p. Six hours later, the mice were bled, sera collected, pooled, and assayed for CSF activity as described in the Materials and Methods section. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate samples of serum pools from three separate experiments in which 5 mice per treatment per experiment were pooled.

Figure 17B. MPL-induction of early phase tolerance to E. coli LPS — ICR mice (5 mice/group) were injected on day 0 with either saline, E. coli LPS (25  $\mu$ g/mouse), or the indicated concentration of MPL (1-100  $\mu$ g/mouse). On day 3, mice were challenged with E. coli K235 LPS (25  $\mu$ g/mouse). Six hours later sera were collected and assayed for CSF activity as described in the Materials and Methods section. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate samples of serum pools from three separate experiments in which 5 mice per treatment per experiment were pooled. The treatment designation in Figure 17B indicates the treatments which were administered on day 0/day 3, respectively.





(Youngner and Stinebring, 1965). Figure 18 illustrates that the level of serum IFN induced by MPL was comparable to that stimulated by *E. coli* LPS; however, the tolerance induced by MPL for IFN was less than the tolerance induced by the intact LPS for IFN (30% vs. 99% suppression of the IFN response) or the MPL-induced tolerance for CSF (see Figure 17B).

It was also found that prior exposure to an initial dose of MPL (100  $\mu$ g/mouse) increased significantly the LD<sub>50</sub> (approximately 5-fold) and essentially eliminated overt symptoms of endotoxicity, i.e., ruffled fur, conjunctival discharge, and diarrhea in response to a sublethal challenge of LPS. These data are shown in Table XII.

MPL-induced changes in the number of bone marrow-derived macrophage progenitor cells — To test the efficacy of MPL to increase bone marrow M-CFU (as shown earlier for *E. coli* LPS; see Figure 5B), groups of 5 mice were injected with saline, *E. coli* LPS (25  $\mu$ g/mouse), or varying concentrations of MPL, and on the third day following injection, bone marrow cells from the femurs of each group were enumerated and cultured in an excess of CSF-1 to determine the number of M-CFU. The results in Figure 19 indicate that MPL increased the number of M-CFU in the bone marrow in a dose-dependent fashion. When mice were given 100  $\mu$ g MPL per mouse, the level of M-CFU per femur was equal to that induced by 25  $\mu$ g *E. coli* LPS.

These findings were further supported by changes in

Figure 18. Interferon induction by MPL and effect of MPL-treatment on LPS-induced interferon production in vivo -- ICR mice (5 mice/group) were injected with saline, *E. coli* LPS (25  $\mu$ g/mouse), or MPL (50 or 100  $\mu$ g/mouse) i.v. on day 0. Three days later, the various groups of mice were injected i.v. with either saline, LPS, or MPL, as indicated. Serum samples were collected 2 h later and assayed for interferon (antiviral) activity as described in the Materials and Methods section. Results represent the arithmetic mean  $\pm$  standard error of the arithmetic mean of antiviral activities of individual serum samples. Along the abscissa are indicated the treatments on days 0 and 3, respectively.




Table XII  
Effect of MPL exposure on LPS-induced LD<sub>50</sub>  
and symptoms of endotoxicity

	Experimental Group <sup>a</sup>		
	Non-tolerized (Saline/LPS)	MPL-tolerized (MPL/LPS)	LPS-tolerized (LPS/LPS)
LD <sub>50</sub> <sup>b</sup>	258 µg	1,156 µg	972 µg
Ruffled fur <sup>c</sup>	10/12	0/15	1/12
Conjunctival discharge <sup>c</sup>	5/12	2/15	0/12
Diarrhea <sup>c</sup>	6/12	1/15	1/12

---


<sup>a</sup> Mice were injected i.p. on day 0 with saline, MPL (100 µg/mouse), or *E. coli* K235 LPS (25 µg/mouse). Three days later, the mice were challenged with *E. coli* LPS for LD<sub>50</sub> determination and assessment of symptoms as described in the Materials and Methods section.

<sup>b</sup> Calculated by the method of Reed and Muench (1939). [The LD<sub>50</sub> for MPL was not determined in this study. The MPL LD<sub>50</sub> has been reported to be greater than 10 mg for mice (Ribi, 1984)].

<sup>a</sup> The proportion of mice clearly exhibiting the indicated symptom 6 h after i.p. injection of *E. coli* K235 LPS (25 µg/mouse) on day 3. Injection of MPL (100 µg/mouse) induced none of the indicated symptoms in any of the 15 mice tested in this experiment.


Figure 19. Effect of a tolerizing injection of MPL on the number of macrophage precursors in the bone marrow -- ICR mice (5 mice/group) were injected on day 0 with either saline, *E. coli* LPS (25 µg/mouse), or MPL (at the indicated doses). Three days later, the bone marrow cells were collected and pooled (5 mice per treatment group).  $5 \times 10^4$  cells from each cell suspension were then plated in duplicate in an excess of CSF-1 and the number of M-CFU determined as described in the Materials and Methods section. The results represent the arithmetic mean  $\pm$  one standard deviation of duplicate determinations.





bone marrow cell sizing profiles obtained using a Coulter Channelyzer. Bone marrow cell suspensions from groups of 5 mice injected 3 days earlier with saline, *E. coli* LPS, or MPL were compared. As can be seen in Figure 20, like LPS, injection of MPL induced a marked reduction in the relative number of bone marrow cells in Peak 1 (20% of total) and a compensatory increase in the number of cells within Peak 2 (80%). This was accompanied by an increase in cell size in Peak 2. As was previously observed with *E. coli* LPS, this change in cell sizing profile induced by MPL coincided temporally with the acquisition of optimal tolerance.

Figure 20. Effect of tolerizing doses of MPL on bone marrow cell sizing profiles — ICR mice (5 mice/group) were injected i.p. on day 0 with either saline, *E. coli* LPS (25 µg/mouse), or MPL (at the indicated doses) and sacrificed three days later. Cell sizing profiles were obtained from suspensions of bone marrow cells using a Coulter Channelyzer. The arrow indicates the initial position of Peak 2 in mice injected with saline on day 0.



## DISCUSSION

For some time, investigators have attempted to clarify the extremely complex cellular mechanisms which underlie responsiveness to Gram negative bacterial endotoxin (LPS). By far, one of the most extensively used animal models has been the C3H/HeJ mouse strain, which, due to the presence of a single autosomal mutation (Watson *et al.*, 1978), is markedly hyporesponsive to LPS (reviewed by Morrison and Ryan, 1979). This genetic defect ( $Lps^d$ ) is reflected in a number of cell types, e.g., decreased mitogenic response of B cells (Sultzer and Nilsson, 1972), reduced ability of C3H/HeJ pre-T cells to express Thy-1 antigen (Koenig *et al.*, 1977) or to proliferate (Vogel *et al.*, 1983) in response to LPS, reduced ability of C3H/HeJ macrophages to respond to LPS (reviewed in Vogel *et al.*, 1981), and the failure of C3H/HeJ fibroblasts to be altered metabolically by LPS (Ryan and McAdam, 1977). Using this model in conjunction with syngeneic LPS-responsive mice ( $Lps^n$ ), much information has been obtained that points to the macrophage as the cell which figures centrally in mediating endotoxicity. Michalek *et al.* (1980) demonstrated that the cells principally responsible for endotoxin responsiveness are radiosensitive and bone marrow-derived. Further, it was shown that many soluble, macrophage-derived factors which are induced by LPS *in vitro* [e.g., endogenous pyrogen (Atkins *et al.*, 1967), colony stimulating factor (Apte *et al.*, 1976; Apte and Pluznik, 1976; Metcalf, 1971; Quesenberry *et al.*, 1972),

interferons (Ho, 1980), and prostaglandins of the E series (Skarnes and Harper, 1972)] are associated with in vivo endotoxicity. In addition, an association between macrophage differentiation and macrophage sensitivity to LPS has been demonstrated (Suter et al., 1958; Benacerraf et al., 1959; Rosenstreich and Vogel, 1980; Moore et al., 1980).

A second, less frequently employed model of LPS-hyporesponsiveness is an inducible state of "endotoxin tolerance", as it was designated originally by Favorite and Morgan (1942). This condition is characterized by a progressive decrease in LPS responsiveness when endotoxin is re-administered at appropriate intervals (reviewed by Greisman, 1983). An "early phase" of endotoxin tolerance occurs within the first few days after exposure to LPS, is transient (subsides within a week), and is not O-antigen-specific (Greisman and Hornick, 1976). Previous studies which employed this model also suggested macrophage participation in the mediation of LPS-induced toxicity. Specifically, it was shown that the levels of endogenous pyrogen and prostaglandins produced in vitro by macrophages derived from tolerized mice were decreased (Dinarelli et al., 1968; Rietschel et al., 1980). The data presented herein demonstrated that the sterile inflammatory agent, thioglycollate, elicited markedly reduced numbers of peritoneal exudate macrophages from endotoxin-tolerized mice (see Table IV). This reduction in the relative numbers of peritoneal macrophages in mice pre-treated with LPS suggested that, in addition to LPS-induced macrophage

refractoriness to LPS, fewer macrophages might be available to respond to LPS in the periphery. Taken together, these findings prompted us to test the hypothesis that early endotoxin tolerance is related to the presence of immature monocytic cells which accumulate in the bone marrow and could, in turn, limit the potential number of LPS-responsive cell types in the periphery.

Using colony stimulating factor (CSF) as an indicator of *in vivo* LPS-responsiveness, we confirmed the findings of Williams *et al.* (1983), that early endotoxin tolerance was optimal at 3 and 4 days after the initial exposure to LPS and that this state of hyporesponsiveness waned within a week. We found that the acquisition of early tolerance followed a normal response to LPS. Optimal levels of serum CSF were demonstrated 6 h after the first exposure to LPS, as had been reported originally by Metcalf (1971). On days 1 and 2 post-LPS injection, the number of nucleated cell types in the bone marrow was markedly reduced. This latter observation was consistent with the findings of Sultz (1969) and Moeller *et al.* (1978) who have shown an efflux of granulocytes and monocytes from the bone marrow into the blood and peritoneum following intraperitoneal injection of LPS. Furthermore, we have shown that the acquisition, maintenance, and loss of tolerance coincides temporally with an increase (followed by a decrease) in the number of macrophage precursors (M-CFU and HPP) in the bone marrow. The increase in macrophage precursor frequency correlated well with: (1) an alteration in bone



marrow cell sizing profiles, (2) an enrichment in a denser cell population which contained all of the precursor activity, and (3) an increase in immature macrophage forms, as shown by cytology. Taken collectively, these results indicated that the development of early endotoxin tolerance is associated with an abrupt depopulation of the nucleated cells in the bone marrow which is replaced by a less mature population of cells enriched for macrophage precursors.

The increase in the level of macrophage precursors was sustained in the bone marrow for at least 24 h after a second (challenge) injection, but returned to normal after a series of repeated injections. Thus, it is possible that in the initial phase of endotoxin tolerance, those macrophages which are available to respond to the second challenge dose of endotoxin are immature and less responsive to the LPS challenge. The hypothesis that immature macrophages are less LPS-responsive has been supported by the independent findings of a number of investigators. Specifically, Neumann and Sorg (1980) showed that bone marrow-derived macrophage precursors grown in the presence of CSF-1, acquire LPS-sensitivity late in culture relative to the acquisition of other macrophage differentiative functions. Similarly, Moore *et al.* (1980) have shown that CSF-1-propagated bone marrow macrophages (from endotoxin responsive mice) coordinately exhibited enhanced differentiation and LPS-sensitivity *in vitro*. In addition, it has been shown that lymphokine-rich culture supernatants induced increased differentiation of C3H/HeJ macrophages *in*

vitro, and rendered them partially responsive to LPS (Vogel and Mergenhagen, 1982). It is conceivable that the sequential expression of certain functions during macrophage development and differentiation may be a prerequisite for full expression of endotoxin sensitivity. A blockade in development which results in the accumulation of macrophage progenitors in the bone marrow may limit the availability or, if released, dilute the numbers of mature LPS-responsive effector cells in the periphery. This latter possibility was supported by the finding that the number of M-CFU in the spleens of mice injected 3 days previously with E. coli LPS was increased fourteen-fold. One approach which could be taken to test this hypothesis would be to reproduce the hematopoietic alterations seen in response to LPS with a non-endotoxic agent, then subsequently challenge with endotoxin. If the mice were found to be endotoxin hyporesponsive, it would strengthen the notion that the induction of early endotoxin tolerance depends upon a repopulation of the bone marrow with immature macrophages.

The studies of van Waarde et al. (1978) provide possible mechanisms by which increased numbers of macrophage precursors could accumulate in the bone marrow. These investigators have shown that the injection of certain inflammatory agents results in the induction of two soluble factors (i.e., factor increasing monocytopoiesis (FIM) and monocytopoiesis inhibitor (MPI)). FIM was shown to decrease cell cycle time for promonocytes and results in increased numbers of monocytes, while MPI, which is produced after the

inflammatory stimulus has been removed, curtails monoblast proliferation and acts to curtail the action of FIM. Although endotoxin was not utilized as an inflammatory stimulus in these studies, it is possible that the increase in macrophage precursor pools which we observed in tolerized mice resulted from an overproduction of FIM or a failure of LPS-tolerized mice to produce the inhibitor, MPI.

The finding that tolerance is sustained with repeated LPS injections (homologous or heterologous), even though the number of precursors returns to normal levels, suggests that additional mechanisms for sustaining the tolerant state come into play. One possibility is that repeated LPS injections result in the appearance of anti-LPS antibodies which act to clear the endotoxin from the circulation. However, since this was seen for both homologous and heterologous LPS injection sequences, one would need to invoke the presence of either cross-reactive anti-Lipid A or anti-core antibodies which could act to clear both *E. coli* and *Ps. aeruginosa* LPS from the circulation or a polyclonal activation event, in which B cell clones with antibody specificities for an assortment of LPS species are expanded. Although the LPS and Lipid A of *Ps. aeruginosa* share some structural similarities with those produced by *E. coli* (Wilkinson, 1977), neither the Lipid A nor the core moieties are extremely antigenic in the mouse (Galanos *et al.*, 1971). For this reason, the first possibility is less likely. Nevertheless, since it is well known that LPS acts as a polyclonal B-cell activator, such that a spectrum of antibody

specificities is induced (Andersson *et al.*, 1972), repeated injections of either homologous or heterologous LPS could possibly expand B-cell clones with specificity for a heterologous LPS preparation.

A second possible mechanism to account for the finding that tolerance is sustained even after M-CFU numbers return to normal comes primarily from the work of Ulevitch *et al.* (1979, 1981, 1984). These authors reported that the binding of LPS to high density lipoprotein (HDL) markedly affected the kinetics and specificity of LPS-cell interactions and the biological activity of LPS. Specifically, pyrogenic activity and the ability of LPS to induce neutropenia in rabbits were inhibited. Further studies were performed by Ulevitch and co-workers to compare the binding of LPS to HDL in normal rabbit serum and serum derived from LPS-pretreated rabbits. Their results suggested that a new protein, which they termed gp60, was produced as an "acute phase reactant" (as defined by Sipe and Rosenstreich, 1981) in response to LPS, and that gp60 increased the binding of LPS to HDL. Perhaps increased LPS-HDL binding, facilitated by an LPS-induced acute phase reactant, occurs following repeated injections with homologous or heterologous LPS preparations. This, in turn, could limit the availability of LPS to induce toxic effects, even after the number of immature macrophages had returned to normal. Such a mechanism could be operative, even in heterologous injection sequences, without invoking the presence of antibodies to clear the LPS. The effect of acute phase proteins on LPS activity and their



relationship to the tolerant state remains to be explored.

It is also possible that the alterations in macrophage progenitor numbers is an epiphenomenon; the actual mechanism which underlies acquired unresponsiveness to LPS is that exposure of macrophages to LPS renders them refractory to subsequent stimulation. This could be due to receptor blockade and/or down-modulation of the putative "LPS receptor" from the surface of the cell. The findings of Sullivan et al. (1983) are consistent with such an hypothesis. These investigators found that in response to an initial exposure to endotoxin in vitro, human monocytes produced CSF; however, the cultures rapidly became refractory to further stimulation by LPS, such that by the fourth day in culture, CSF secretion was not detectable. The diminished response was shown not to be due to degradation or "detoxification" of endotoxin, accumulation of a soluble inhibitor of monocyte synthesis, or negative feedback inhibition by newly-synthesized CSF. To date, theirs is the only report which suggests that human monocytes can be rendered tolerant to LPS by in vitro exposure to LPS. Precedent for receptor down-regulation following ligand-receptor interaction has been demonstrated in a number of systems. For example, after epidermal growth factor (EGF) binds to specific receptors on target cells, aggregation of the hormone-receptor complexes occurs and occupied EGF receptors in coated pits are endocytosed. The rapid degradation of receptor molecules by lysosomal enzymes results in their down-regulation because the receptor molecules cannot be recycled to the membrane

(Schlessinger *et al.*, 1984). Other studies have shown that down-regulation of insulin receptors occurs following binding of insulin to its receptor (Marshall and Olefsky, 1979; Conti *et al.* 1976; Marshall and Olefsky, 1980). This receptor-ligand interaction induces clustering of insulin receptors (Schlessinger *et al.*, 1978), and this clustering leads to internalization of the ligand-receptor complex and, like EGF, a failure to recycle the receptor to the cell membrane (Anderson *et al.*, 1976).

In the second section of this study, we sought to characterize further the cell types which participated in the induction of early endotoxin tolerance. To this end, other murine models with deficiencies or altered responses in specific cellular compartments were subjected to the same tolerizing regimen which had been established for outbred ICR mice. Early endotoxin tolerance was induced in inbred, LPS-responsive ( $Lps^n$ ) C3H/OuJ mice, but not in syngeneic, LPS-hyporesponsive C3H/HeJ ( $Lps^d$ ) mice, as assessed by increased serum CSF, bone marrow M-CFU numbers, and a marked shift in bone marrow cell sizing profile. These results indicated that expression of the  $Lps^d$  gene defect resulted in: (1) an inability to respond to an initial exposure of LPS to produce serum CSF [as had been reported previously (Apte *et al.* 1976)]; and (2) no alteration in either bone marrow M-CFU numbers or in the bone marrow cell sizing profile. These findings are consistent with the hypothesis that C3H/HeJ mice fail to respond to LPS due to an  $Lps^d$ -encoded membrane defect

(Coutinho *et al.* 1977; Jakobovitz *et al.* 1982). If the mechanism(s) by which C3H/HeJ and endotoxin-tolerized mice fail to respond to LPS were the same, one would expect to observe both a shifted bone marrow cell sizing profile and increased M-CFU numbers in untreated C3H/HeJ mice. Neither were observed in this study. However, one report in the literature has suggested that M-CFU numbers are increased in C3H/HeJ mice when compared with C3HeB/FeJ ( $Lps^n$ ) mice (MacVittie and Weinberg, 1980). Further studies will be required to confirm these observations in light of recent findings that C3HeB/FeJ mice express other gene defects (distinct from  $Lps^d$ ) which may compromise the functioning of their macrophages (O'Brien and Rosenstreich, 1983).

Whereas normal responsiveness to endotoxin was not seen in C3H/HeJ ( $Lps^d$ ) mice, BALB/c euthymic ( $nu/+$ ) and athymic ( $nu/nu$ ) mice responded comparably to LPS to produce CSF and to become tolerized. The nude mice used in this study were found to be extremely T-cell deficient by FACS analysis of their splenocytes (Table VIII). These findings suggested that T cells do not contribute significantly to the generation of LPS-induced serum CSF or to the induction of early endotoxin tolerance. Previous studies indicated that the presence of the nude gene on either an  $Lps^n$  or  $Lps^d$  background failed to alter LPS-responsiveness or hyporesponsiveness, respectively (Vogel *et al.*, 1979).

CBA/N mice express an X-linked genetic lesion ( $xid$ ) which results in a failure to respond to certain B cell



mitogens, including LPS (Amsbaugh *et al.*, 1974; Scher, 1982). This genetic defect manifests itself as an absence of the Lyb 5 positive B cell subset in these mice (Ahmed *et al.*, 1977). In the present study, a third murine model, the C3.CBA/N mouse strain was utilized because it carries this X-linked genetic defect (Mond *et al.*, 1983). This strain was developed by introducing the xid gene into the C3H/HeN inbred mouse strain by repeated cycles of backcrossing. The initial cross consisted of mating a female CBA/N (homozygous for the xid gene) with a male C3H/HeN. One of the male progeny (hemizygous for the xid gene) was then backcrossed to his mother. Lastly, females from this cross, now termed C3.CBA/N and homozygous for the xid gene, were crossed with male C3H/HeN mice. C3.CBA/N mice used in this study were at the 13th cycle of this backcrossing procedure. The probability of homozygosity at a specific locus after 12 generations of backcrossing to an inbred strain has been calculated to be 99.9% (Klein, 1975).

Mond *et al.* (1983) verified that, like CBA/N mice, C3.CBA/N spleen cells have a greatly reduced response to LPS *in vitro* and the B cell deficit in this mouse strain could be demonstrated by FACS analysis of cells from the spleen, lymph nodes, and Peyer's patches. It was shown that there are 21.9%, 2.7% and 18.0% sIgM positive cells, respectively, in these organs from the C3.CBA/N mouse, whereas cells from C3H/HeN spleen, lymph nodes, and Peyer's patches yielded 51.9%, 20.9% and 30.4% sIgM positive cells, respectively. In the current study, these mice responded normally to an initial injection of

LPS with a characteristic increase in the level of serum CSF. This increase was shown to be suppressed after a second (challenge) injection of LPS on day 3. C3.CBA/N mice also displayed the tolerized bone marrow profile and an increase in bone marrow M-CFU numbers 3 days post-LPS injection. Mice which express the *xid* defect have been shown to respond normally to the toxic effects of LPS *in vivo*, and their macrophages produce normal levels of IL 1 in response to LPS *in vitro* (Rosenstreich *et al.*, 1978). Thus, the population of LPS-responsive B cells which is deficient in this strain does not appear to play an essential role in either LPS responsiveness or the induction of endotoxin tolerance.

The recent findings of Williams *et al.* (1983) indicated that injection of normal spleen cells into LPS-tolerized ICR mice restored the capacity to respond to LPS, as assessed by serum CSF induction. These investigators, however, made no attempt to tolerize normal ICR mice by transfer of spleen cells from tolerized mice to normal mice because the number of cells necessary to override the normal level of responsiveness was deemed by the investigators to be experimentally prohibitive (D. Pluznik, personal communication). In order to evaluate the contribution of the spleen in CSF production and in the induction of tolerance, splenectomized ICR mice were subjected to the standard tolerizing protocol which was established for normal mice. The data indicate that the presence or absence of a spleen had no influence on the ability of mice to respond to LPS to produce serum CSF and to be tolerized. Thus, spleen

cells cannot be considered as a major source of LPS-induced CSF, as suggested by Williams et al. (1983). This supports the alternative suggestion by Williams et al. (1983) that other organs, such as lungs or resident peritoneal macrophages, may contribute significantly to the production of soluble serum factors after administration of LPS. Changes in M-CFU numbers and alterations in bone marrow cell sizing profiles in tolerized, splenectomized mice were also consistent with the notion that the spleen plays little role, if any, in these manifestations of LPS-induced tolerance.

The next phase of this project sought to establish whether acquired resistance to LPS could extend to protection against bacterial infection. The responses observed in the early phase of endotoxin tolerance and endotoxin-induced stimulation of resistance to infections are antibody independent (Milner, 1971). Studies by Landy (1956) showed that various bacterial lipopolysaccharides evoked in mice a rapidly developing, non-specific increase in resistance to different Gram negative bacterial infections. The development of increased resistance to infection by E. coli, Proteus vulgaris, Ps. aeruginosa and Salmonella typhosa following LPS injection was shown by Landy and Pillemer (1956) to be associated with elevated properdin levels, which, in control animals was found to fall progressively as they became infected. These investigators also showed that resistance to Ps. aeruginosa infection was increased optimally 24 h after injection of 1  $\mu$ g Salmonella typhosa LPS i.p. (65% survivors),

but was reduced only slightly (50% survivors) if mice were injected with Ps. aeruginosa 72 h or 120 h after LPS administration.

Increased resistance to infection stimulated by LPS may also be related to the production in vivo of a number of biologically active materials which have been found to stimulate macrophages to become activated. Production of CSF during infections is associated with enhanced functional activities of macrophages. CSF has been shown to stimulate macrophages to produce prostaglandins (Kurland et al., 1979), plasminogen activator (Lin and Gordon, 1979), and Interleukin 1 (Moore et al., 1980). In one report, Handman and Burgess (1979) demonstrated that partially purified granulocyte-macrophage colony stimulating factor caused a dramatic increase in the uptake and killing of the intracellular parasite, Leishmania tropica by macrophages. Trudgett et al. (1973) studied the effect of CSF on the in vitro phagocytic and microbicidal activity of mouse peritoneal macrophages incubated with Salmonella typhimurium. They found that CSF induced a significant enhancement of S. typhimurium killing by macrophages, although there was no effect on the number of bacteria phagocytosed. Another macrophage product that is produced in response to LPS is interferon (Youngner and Stinebring, 1965). Infection of experimental animals with E. coli (Weinstein et al., 1970) or Listeria monocytogenes (Remington and Merrigan, 1970) has been shown to be suppressed by prior injection of interferon or interferon inducers.

Lastly, the survival rate of mice injected with Klebsiella pneumoniae one day after injection with endotoxin or other known interferon inducers was shown to be increased (Pindak, 1970).

In order to determine the temporal relationship of early phase endotoxin tolerance to LPS-induced non-specific resistance to infection, control and tolerized ICR mice were challenged with Pseudomonas aeruginosa using the burn model of Pavlovskis et al. (1977). The rapid progression of fatal Gram negative infection associated with this model was necessary if resistance to infection were to be detected during the transient early phase tolerance period (refer back to Figure 1). The two bacterial products most likely implicated in the systemic infection caused by Ps. aeruginosa are lipopolysaccharide and exotoxin A. Evidence associating Ps. aeruginosa endotoxin with sepsis is extensive (reviewed by Young, 1979). Exotoxin A (Liu, 1966) in its purified form is highly lethal for animals and produces shock in dogs (Atik et al., 1968) and rhesus monkeys (Pavlovskis et al., 1975). Tolerized mice initially displayed a high degree of resistance when compared to similarly infected control mice, but such resistance was shown to wane rapidly (2 days post-bacterial challenge; 5 days post-LPS administration), at a time when early endotoxin tolerance would normally be less than optimal (see Figure 1). It is interesting to note that a statistically significant delay in death was observed only at the highest two doses of bacteria. This may reflect a contribution of LPS from the bacterial challenge, which acts to serve as an additional



"tolerizing" injection. Morrison and Curry (1979) have estimated that approximately 40  $\mu$ g of LPS could be expected from 10<sup>10</sup> Gram negative organisms. In consideration of these results, repeated tolerizing injections prior to bacterial infection would have, perhaps, proven to be more efficacious in the protection of mice against Pseudomonas infection. A reduced time interval between LPS administration and bacterial challenge also could have yielded a greater degree of resistance to infection.

The major obstacle which has limited the clinical application of endotoxin for its beneficial effects has been its toxic side effects. Chemical modification of the endotoxin molecule has resulted in a non-toxic, Lipid A derivative, monophosphoryl Lipid A (MPL) (Qureshi et al., 1982) which is greatly reduced in its toxic activity. In the final section of this study, the efficacy of MPL to replace intact LPS in the early endotoxin tolerance protocol was examined. Unlike initial exposure to wild type LPS, MPL did not induce symptoms of endotoxicity, i.e., ruffled fur, conjunctival discharge, or diarrhea, even at a dose of 100  $\mu$ g per mouse. Despite the absence of these overt manifestations of endotoxicity, MPL was shown to induce both serum colony stimulating factor and interferon to levels induced by wild type LPS. It was also found that injection of MPL on day 0 reduced the LPS-induced serum CSF upon challenge with wild-type E. coli LPS 3 days later. MPL was also shown to increase greatly the LD<sub>50</sub> to challenge injection with E. coli LPS and effectively reduce

overt symptoms of endotoxicity upon challenge with intact LPS. As seen in the LPS-induced tolerance system, which was established in the first phase of this study, MPL administration greatly increased the number of macrophage progenitor cells in the bone marrow and this increase in M-CFU coincided with an increase in cell size and cell number in Coulter Channelyzer profile "Peak 2". Taken collectively, these results indicate that MPL possesses the necessary structural component(s) required to induce a state of early endotoxin tolerance. Most importantly, MPL failed to induce the initial toxic reactions typically observed with wild-type endotoxin or diphosphoryl Lipid A preparations. One intriguing aspect of this study was that tolerance, as assessed by IFN production, was much less affected by MPL than were the other manifestations of LPS responsiveness. One possible implication is that IFN may be less involved in the induction of the toxic effects of LPS than other serum factors, such as CSF. In this regard, previous work by Moore *et al.* (1980) supports a role for CSF as an immunoregulatory agent capable of rendering macrophages more sensitive to LPS *in vitro*, as assessed by increased production of IFN and Interleukin 1.

In summary, an early phase endotoxin tolerance model was established in mice based on a system developed by Williams *et al.* (1983). The results presented herein indicate that the state of early tolerance is associated with marked alterations in bone marrow progenitor pools. The cellular mechanisms which underlie this state of induced hyporesponsiveness were probed



further using various murine models to assess the relative contribution of certain lymphoid cell subsets. The temporal association of early phase tolerance and non-specific resistance to Gram negative infection was examined using Pseudomonas aeruginosa as the infecting agent. Lastly, a non-toxic Lipid A derivative, monophosphoryl Lipid A, was shown to be efficacious as an inducer of early phase tolerance. These findings, taken collectively, extend our present understanding of the cellular mechanisms which contribute to the acquisition of hyporesponsiveness to the toxic manifestations of endotoxin. An understanding of acquired LPS-hyporesponsiveness in experimental animals should further our understanding of LPS responsiveness. Moreover, the use of non-toxic derivatives of LPS to induce a hyporesponsive state to the toxic effects of endotoxin holds great potential for their use in therapeutic intervention.

## BIBLIOGRAPHY

Abernathy, R.S. 1957. Homologous and heterologous resistance in mice given bacterial endotoxins. J. Immunol. 78:387.

Ahmed, A., I. Scher, S.O. Sharrow, A.H. Smith, W.E. Paul, D.H. Sachs, and K.W. Sell. 1977. B lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens. J. Exp. Med. 145:101.

Amsbaugh, D.F., C.T. Hansen, B. Prescott, P.W. Stashak, R. Asofsky, and P.J. Baker. 1974. Genetic control of the antibody response to type III pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J. Exp. Med. 136:931.

Anderson, R.G.W., J.L. Goldstein, and M.S. Brown. 1976. Localization of low density lipoprotein receptors on plasma membrane of normal human fibroblasts and their absence in cells from a familial hypercholesterolemia homozygote. Proc. Natl. Acad. Sci. U.S.A. 73:2434.

Andersson, J., O. Sjöberg, and G. Möller. 1972. Induction of immunoglobulin and antibody synthesis in vitro by lipopolysaccharide. Eur. J. Immunol. 2:349.

Apte, R.N., C. Galanos, and D.H. Pluznik. 1976. Lipid A, the active part of bacterial endotoxin in inducing serum colony stimulating activity and proliferation of splenic granulocyte-macrophage progenitor cells. J. Cell. Physiol. 87:71.

Apte, R.N. and D.H. Pluznik. 1976. Control mechanisms of endotoxin and particulate material stimulation of hemopoietic colony forming cell differentiation. Exp. Hematol. 4:10.

Atik, M., P.V. Liu, B.A. Hanson, S. Amini, and C.F. Rosenberg. . 1968. Pseudomonas exotoxin shock: A preliminary report of studies in dogs. JAMA. 205:134.

Atkins, E., P. Bodel, and L. Francis. 1967. Release of an endogenous pyrogen in vitro from rabbit mononuclear cells. J. Exp. Med. 126:357.

Barry, G.T., V. Abbott, and T. Tsai. 1962. Relationship of colominic acid (poly N-acetylneuraminic acid) to bacteria which contain neuraminic acid. J. Gen. Microbiol. 29:335.

Beaty, H.N. 1983. Diseases caused by gram negative cocci--meningococcal infections. In: Harrison's Principles of Internal Medicine, 10th Edition. R.G. Petersdorf, R.D. Adams, E. Braunwald, K.J. Isselbacher, J.B. Martin, J.D. Wilson (eds.). Mc Graw-Hill. New York. p.936.

Beeson, P.B. 1946. Development of tolerance to typhoid bacterial pyrogen and its abolition by reticuloendothelial blockade. *Proc. Soc. Exp. Biol. Med.* 61:248.

Beeson, P.B. 1947a. Tolerance to bacterial pyrogens. I. Factors influencing its development. *J. Exp. Med.* 86:29.

Beeson, P.B. 1947b. Tolerance to bacterial pyrogens. II. Role of the reticuloendothelial system. *J. Exp. Med.* 86:39.

Beeson, P.B. 1948. Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytes (Abstract). *J. Clin. Invest.* 27:524.

Benacerraf, B., G.J. Throbecke, and D. Jacoby. 1959. Effect of zymosan on endotoxin toxicity in mice. *Proc. Soc. Exp. Biol. Med.* 100:796.

Berry, L.J. 1977. Bacterial toxins. *Crit. Rev. Toxicol.* 5:239.

Bertoncello, I., T.R. Bradley, and G.S. Hodgson. 1981. Characterization and enrichment of macrophage progenitor cells from normal and 5-fluorouracil treated mouse bone marrow by unit gravity sedimentation. *Exp. Hematol.* 9:604.

Bradley, T.R. and G.S. Hodgson. 1979. Detection of primitive macrophage progenitor cells in mouse bone marrow. *Blood* 54:1446.

Braude, A.I., F.J. Carey, and M. Zalesky. 1955. Studies with radioactive endotoxin. II. Correlation of physiologic effects with distribution of radioactivity in rabbits injected with lethal doses of *E. coli* endotoxin labelled with radioactive sodium chromate. *J. Clin. Invest.* 34:858.

Centanni, E. 1894. Untersuchungen uber das Infectionsfieber - das Fiebergift der Bacterien. *Dtsch. Med. Wochenschr.* 20:148.

Centanni, E. 1942. Immunitaeterscheinungen im experimentellen Fieber mit besonderer Beruecksichtigung des pyrogenen Stoffes aus Typhusbazillen. *Klin. Wochenschr.* 21:664.

Cluff, L.E. 1971. Effects of lipopolysaccharides (endotoxins) on susceptibility to infections. In: *Microbial Toxins*. Vol. V. S. Kadis, G. Weinbaum, and S.J. Ail (eds.). Academic Press, New York. p.399.

Conti, M., J.P. Harwood, A.J.W. Hsueh, M.L. Dufau, and K.J. Catt. 1976. Gonadotropin-induced loss of hormone receptors and desensitization of adenylate cyclase in the ovary. *J.*

Biol. Chem. 251:7729.

Coutinho, A., L. Forni, F. Melchers and T. Watanabe. 1977. Genetic defect in responsiveness to the B cell mitogen lipopolysaccharide. Eur. J. Immunol. 7:325.

Coutinho, A., L. Forni, and T. Watanabe. 1978. Genetic and functional characterization of an antiserum to the lipid A-specific triggering receptor on murine B lymphocytes. Eur. J. Immunol. 8:63.

Cremer, N. and D.W. Watson. 1957. Influence of stress on distribution of endotoxin in RES determined by fluorescein antibody technic. Proc. Soc. Exp. Biol. Med. 95:510.

Devoe, I.W. and J.E. Gilchrist. 1973. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J. Exp. Med. 138:1156.

Dinareello, C.A., P.T. Bodel, and E. Atkins. 1968. The role of the liver in the production of fever and in pyrogenic tolerance. Trans. Assoc. Am. Phys. 81:334.

Dubois, M., K.A. Gilles, P.A. Rebers, and F. Smith. 1956. Colorimetric method for determination of sugars and related substances. Anal. Chem 28:350.

Favorite, G.O. and H.R. Morgan. 1942. Effects produced by the intravenous injection in man of a toxic antigenic material derived from *Eberthella typhosa*: clinical, hematological, chemical and serological studies. J. Clin. Invest. 21:589.

Flanagan, S.P. 1966. "Nude"--A new hairless gene with pleiotropic effects in the mouse. Genet. Res. 8:295.

Forni, L. and A. Coutinho. 1978. An antiserum which recognizes lipopolysaccharide reactive B cells in the mouse. Eur. J. Immunol. 8:56.

Freeman, C.G. 1942. The preparation and properties of a specific polysaccharide from bacteria typhimurium Ty<sub>2</sub>. Biochem. J. 36:340.

Friedberg, D. and M. Shilo. 1970. Interaction of Gram negative bacteria with the lysosomal fraction of polymorphonuclear leukocytes. Infect. Immune: 1:305.

Galanos, C., M. Freudenberg, S. Hase, F. Jay and E. Ruschmann. 1977. Biological activities and immunological properties of Lipid A. In: Microbiology 1977. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.269.

Galanos, C. and O. Lüderitz. 1975. Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms.



Eur. J. Biochem. 54:603.

Galanos, C., O. Lüderitz, and O. Westphal. 1971. Preparation and properties of antisera against the lipid A component of bacterial lipopolysaccharides. Eur. J. Biochem. 24:116.

Galanos, C., E.T. Rietschel, O. Lüderitz, and O. Westphal. 1971. Interaction of lipopolysaccharides and Lipid A with complement. Eur. J. Biochem. 19:143.

Gemski, P. and S.B. Formal. 1975. Shigellosis: an invasive infection of the gastrointestinal tract. In: Microbiology 1975. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.165.

Gemski, P., Jr., D.G. Sheahan, O. Washington, and S.B. Formal. 1972. Virulence of Shigella flexneri hybrids expressing Escherichia coli somatic antigens. Infect. Immun. 6:104.

Goud, T.J.L.M., C. Schotte, and R. van Furth. 1975. Identification and characterization of the monoblast in mononuclear phagocyte colonies grown in vitro. J. Exp. Med. 142:1180.

Glode, L.M. and D.L. Rosenstreich. 1976. Genetic control of B cell activation by bacterial lipopolysaccharide is mediated by multiple distinct genes or alleles. J. Immunol. 117:2061.

Gmeiner, J., M. Simon, and O. Lüderitz. 1971. The linkage of phosphate groups and of 2-keto-3-deoxyoctonate to the lipid A component in a Salmonella minnesota lipopolysaccharide. Eur. J. Biochem. 21:355.

Greisman, S.E. 1983. Induction of endotoxin tolerance. In: Beneficial Effects of Endotoxins. Alois Nowotny (ed.). Plenum Press, New York. p.149.

Greisman, S.E. and R.B. Hornick. 1976. Endotoxin tolerance. In: The Role of Immunologic Factors in Infectious, Allergic, and Autoimmune Processes. R.F. Beers and E.G. Basset (eds.) Raven Press, N.Y. p.43.

Greisman, S.E. and W.E. Woodward. 1965. Mechanisms of endotoxin tolerance. III. The refractory state during continuous intravenous infusions of endotoxin. J. Exp. Med. 121:911

Greisman, S.E., E.J. Young, and W.E. Woodward. 1966. Mechanisms of endotoxin tolerance. IV. Specificity of the pyrogenic refractory state during continuous intravenous infusions of endotoxin. J. Exp. Med. 124:983.

Habu, S. and K. Okumura. 1984. Cell surface antigen marking the stages of murine T cell ontogeny and its functional

subsets. Imm. Rev. 82:117.

Hahn, H.H., D.C. Char, W.B. Postel, and W.B. Wood Jr. 1967. Studies on the pathogenesis of fever. XV. The production of endogenous pyrogen by peritoneal macrophages. J. Exp. Med. 126:385.

Handman, E.H. and A.W. Burgess. 1979. Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J. Immunol. 122:1134.

Heyman, A. 1945. The treatment of neurosyphilis by continuous infusion of typhoid vaccine. Vener. Dis. Inform. 26:51.

Ho, Monto. 1980. Cellular sources of endotoxin-induced interferons. In: Microbiology 1980. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.128.

Ikehara, S., R.N. Pahwa, G. Fernandez, C.T. Hansen, and R.A. Good. 1984. Functional T cells in athymic nude mice. Proc. Natl. Acad. Sci. 81:886.

Jacobs, D.M. 1984. Structural features of binding of lipopolysaccharides to murine lymphocytes. Rev. Inf. Dis. 6:501.

Jakobovits, A., N. Sharon, I. and Zan-Bar. 1982. Acquisition

of mitogenic responsiveness by nonresponding lymphocytes upon insertion of appropriate membrane components. *J. Exp. Med.* 156:1274.

Jansson, P., A.A. Lindberg, B. Lindberg, and R. Wollin. 1981. Structural studies on the hexose region of the core in lipopolysaccharides from Enterobacteriaceae. *Eur. J. Biochem.* 115:571.

Jennings, H.J., A.K. Bhattacharjee, L. Kenne, C.P. Kenny, and G. Calver. 1980. The R-type lipopolysaccharides of Neisseria meningitidis. *Can. J. Biochem.* 58:128.

Jennings, H.J., G.B. Hawes, G.A. Adams, and C.P. Kenny. 1973. The chemical composition and serological reactions of lipopolysaccharides from serogroups A, B, X, and Y Neisseria meningitidis. *Can. J. Biochem.* 51:1347.

Johnson, A.G. and A. Nowotny. 1964. Relationship of structure to function in bacterial O antigens. III. Biological properties of endotoxins. *J. Bacteriol.* 87:809.

Kabir, S. and D.L. Rosenstreich. 1977. Binding of bacterial endotoxin to murine spleen lymphocytes. *Infect. Immun.* 15:156.

Kadis, S., G. Weinbaum, and S.J. Ajl. 1971. Bacterial endotoxins. In: *Microbial toxins*. Vol. V. Academic Press,

New York. p.1.

Kern, M. 1984. Selective binding of Lipid A to responder and nonresponder B lymphocyte subpopulations. Rev. Inf. Dis. 6:506.

Kindred, B. 1981. Deficient and sufficient immune systems in the nude mouse. In: Immunologic Defects in Laboratory Animals. I. M.E. Gershwin and B. Merchant (eds.). Plenum Press, New York. p. 215.

Klein, J. 1975. In: Biology of the mouse.

Histocompatibility-2 complex. Springer-Verlag, NY. p.33.

Koenig, S., M.K. Hoffmann, and L. Thomas. 1977. Induction of phenotypic lymphocyte differentiation in LPS unresponsive mice by an LPS-induced serum factor and by lipid-A-associated protein. J. Immunol. 118:1910.

Kurland, J.I., L.M. Pelus, P. Ralph, R.S. Bockman, and M.A.S. Moore. 1979. Induction of prostaglandin E synthesis in normal and neoplastic macrophages: Role for colony-stimulating factor (s) distinct from effects on myeloid progenitor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 76:2326.

Landy, M. 1956. Increased resistance to infection developed rapidly after administration of bacterial lipopolysaccharide. Fed. Proc. 15:598.

Landy, M. and L.P. Pillemer. 1956. Increased resistance to infection and accompanying alteration in properdin levels following administration of bacterial lipopolysaccharide. J. Exp. Med. 104:383.

Lin, H.S. and S. Gorden. 1979. Secretion of plasminogen activator by bone marrow-derived mononuclear phagocytes and its enhancement by colony stimulating factor. J. Exp. Med. 150:231.

Liu, P.V. 1966. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. II. Effects of lecithinase and protease. J. Infect. Dis. 116:112.

Luderitz, O., C. Galanos, V. Lehmann, M. Nurminen, E.T. Rietschel, G. Rosenfelder, M. Simon, and O. Westphal. 1973. Lipid A: chemical structure and biological activity. J. Infect. Dis. 128 (Suppl.):9.

MacVittie, T.J. 1979. Alterations induced in macrophage and granulocyte-macrophage colony-forming cells by a single injection of mice with Corynebacterium parvum. J. Reticuloendothel. Soc. 26:479.

MacVittie, T.J. and S.R. Weinberg. 1980. An LPS responsive cell in C3H/HeJ mice: The peritoneal exudate-derived macrophage

colony-forming cell (M-CFC). In: Genetic Control of Natural Resistance to Infection and Malignancy. E. E. Skamene, P. Kongshavn, and M. Landy (eds.). Academic Press, New York. p. 511.

Madonna, G.S. and R.C. Allen. 1981. Shigella sonnei phase I and phase II: susceptibility to direct serum lysis and opsonic requirements necessary for stimulation of leukocyte redox metabolism and killing. Infect. Immun. 32:153.

Mannel, D.N., R.N. Moore, and S.E. Mergenhagen. 1980. Endotoxin-induced tumor cytotoxic factor. In: Microbiology 1980. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.141.

Marshall, S. and J.M. Olefsky. 1979. Effect of lysosomotropic agents on insulin interactions with adipocytes. J. Biol. Chem. 254:10153.

Marshall, S. and J. Olefsky. 1980. Effects of insulin incubation on insulin binding, glucose transport, and insulin degradation by isolated rat adipocytes. J. Clin. Invest. 66:763.

McGhee, J.R., J.J. Farrar, S.M. Michalek, S.E. Mergenhagen, and D.L. Rosenstreich. 1979. Cellular requirements for lipopolysaccharide adjuvant activity. J. Exp. Med. 149:793.



McIntire, F.C., H.W. Sievert, G.H. Barlow, R.A. Finley, and A.Y. Lee. 1967. Chemical, physical, and biological properties of a lipopolysaccharide from Escherichia coli K235. *Biochemistry* 6:2363.

Medearis, D.N., B.M. Camitta, and E.C. Heath. 1968. Cell wall composition and virulence in Escherichia coli. *J. Exp. Med.* 128:399.

Metcalf, D. 1971. Acute antigen-induced elevation of serum colony stimulating factor (CSF) levels. *Immunology* 21:427.

Metcalf, D. and G.R. Johnson. 1981. Production by spleen and lymph node cells of conditioned medium with erythroid and haemopoietic colony stimulating activity. *Brit. J. Haem.* 48:147.

Michalek, S.M., R.N. Moore, J.R. McGhee, D.L. Rosenstreich, and S.E. Mergenhagen. 1980. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxins. *J. Infect. Dis.* 145:55.

Milner, K.C., J. Rudbach, and E. Ribl. 1971. General characteristics of endotoxin. In: *Microbial Toxins*. Vol. IV, S. Kadis, G. Weinbaum, and S.J. Ajl (eds.). Academic Press, New York. p. 1.

Mita, A., O. Hidedazu, and T. Mita. 1982. Induction of splenic T cell proliferation by Lipid A in mice immunized with sheep red blood cells. *J. Immunol.* 128:1709.

Moeller, G.R., L. Terry, and R. Snyderman. 1978. The inflammatory response and resistance to endotoxin in mice. *J. Immunol.* 120:116.

Mond, J.J., S. Kessler, F.D. Finkleman, W.E. Paul, and I. Scher. 1980. Heterogeneity of Ia expression on normal B cells, neonatal B cells, and on cells from B cell-defective CBA/N mice. *J. Immunol.* 124:1675.

Mond, J.J., G. Norton, W.E. Paul, I. Scher, F.D. Finkleman, S. House, M. Schaefer, P.K.A. Mongini, C. Hansen, and C. Bona. 1983. Establishment of an inbred line of mice which express a synergistic immune defect precluding *in vitro* responses to type 1 and type 2 antigen, B mitogens and a number of T cell derived helper factors. *J. Exp. Med.* 158:1401.

Moore, R.N. 1982. Regulation of macrophage accessory functions by interactions involving lymphokines and endotoxin. *Klin. Wochenschr.* 60:754.

Moore, R.N., K.J. Goodrum, and L.J. Berry. 1976. Mediation of an endotoxic effect by macrophages. *J. Reticuloendothel. Soc.*

19:187.

Moore, R.N., J.J. Oppenheim, J.J. Farrar, C.S. Carter, A. Waheed, and R.K. Shaddock. 1980. Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony stimulating factors. *J. Immunol.* 125:1302.

Moore, R.N., P.S. Steeg, D.N. Mannel, and S.E. Mergenhagen. 1980. Role of lipopolysaccharide in regulating colony-stimulating factor-dependent macrophage proliferation in vitro. *Infect. Immun.* 30:797.

Moore, R.N., S.N. Vogel, L.M. Wahl, and S.E. Mergenhagen. 1980. Factors influencing lipopolysaccharide-induced interferon production. In: *Microbiology 1980*. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.131.

Morrison, D.C. and B.J. Curry. 1979. The use of polymyxin B and C3H/HeJ mouse spleen cells as criteria for endotoxin contamination. *J. Immunol. Methods* 27:83.

Morrison, D.C. and J.L. Ryan. 1979. Bacterial endotoxins and host immune responses. *Adv. Immunol.* 28:293.

Morrison, D.C. and R.J. Ulevitch. 1978. The effects of

bacterial endotoxins on host mediation systems. Am. J. Pathol. 93:526.

Murphy, A., D.F. Hanson, P.L. Simon, W.F. Willoughby, and B.E. Windle. 1980. Properties of two distinct endogenous pyrogens secreted by rabbit macrophages. In: Microbiology 1980. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.158.

Nelson, B.W. and R.J. Roantree. 1967. Analysis of lipopolysaccharides extracted from penicillin-resistant, serum sensitive Salmonella mutants. J. Gen. Microbiol. 48:179.

Neumann, C. and C. Sorg. 1980. Sequential expression of functions during macrophage differentiation in murine bone marrow liquid cultures. Eur. J. Immunol. 10:834.

Nowotny, A. 1963. Endotoxoid preparations. Nature 197:721.

Nowotny, A. 1983. Beneficial Effects of Endotoxin. Plenum Press, New York.

Nowotny, A. 1969. Molecular aspects of endotoxic reactions. Bacteriol. Rev. 33:72.

O'Brien, A.D. and D.L. Rosenstreich. 1983. Genetic control of the susceptibility of C3HeB/FeJ mice to Salmonella typhimurium

is regulated by a locus distinct from known Salmonella response genes. J. Immunol. 131:2613.

:

Pantelouris, E.M. 1968. Absence of thymus in a mouse mutant. Nature (London) 217:370.

Parant, M. 1968. Recherche d'opsonines chez la souris après stimulation par l'endotoxine de sa résistance à l'infection. Ann. Inst. Pasteur (Paris). 115:264.

Parant, M.A., F.J. Parant, and L.A. Chedid. 1980. Enhancement of resistance to infections by endotoxin-induced serum factor from Mycobacterium bovis BCG-infected mice. Infect. Immun. 28:654.

Pavlovskis, O.R., L.T. Callahan, III, and M. Pollock. 1975. Pseudomonas aeruginosa exotoxin. In: Microbiology 1975. D. Schlessinger (ed.). American Society for Microbiology, Washington, DC. p.252.

Pavlovskis, O.R., M. Pollack, L.T. Callahan III, and B.H. Iglewski. 1977. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect. Immun. 18:596.

pier, G.B., R.B. Markham, and D. Eardley. 1981. Correlation of the biologic responses of C3H/HeJ mice to endotoxin with the

chemical and structural properties of the lipopolysaccharides from Pseudomonas aeruginosa and Escherichia coli. J. Immunol. 127:184.

Pindak, F.F. 1970. Protection of mice against bacterial infection by interferon inducers. Infect. Immun. 1:271.

Quesenberry, P.J., A. Morley, F. Stohlman, Jr., K. Richard, D. Howard, and M. Smith. 1972. Effect of endotoxin on granulopoiesis and colony stimulating factor. N. Engl. J. Med. 286:227.

Qureshi, N., K. Takayama and E. Ribi. 1982. Purification and structural determination of nontoxic Lipid A obtained from lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 257:11808.

Reed, L.J. and H. Muench. 1939. A simple method of estimating fifty percent end points. Am. J. Hyg. 27:493.

Remington, J.J. and T.C. Merigan. 1970. Synthetic polyanions protect mice against intracellular bacterial infection. Nature (London) 226:361.

Ribi, E. 1984. Beneficial modification of the endotoxin molecule. J. Biol. Resp. Modif. 3:1.

Ribi, E., R. Parker, and S.M. Strain. 1979. Peptides as a requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. *Cancer Immunol. Immunother.* 7:43.

Rietschel, E.T., U. Schade, M. Jensen, H.W. Wollenweber, O. Luderitz and S.E. Greisman. 1982. Bacterial endotoxins: Chemical structure, biological activity and role in septicemia. *Scand. J. Infect. Dis.* 31(Suppl.):8.

Rietschel, E.T., U. Schade, O. Luderitz, H. Fischer, and B.A. Peskar. 1980. Prostaglandins in Endotoxemia. In: *Microbiology 1980*. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.66.

Rosenstreich, D.L., S.N. Vogel, A. Jacques, L.M. Wahl, I. Scher and S.E. Mergenhagen. 1978. Differential endotoxin sensitivity of lymphocytes and macrophages from mice with an X-linked defect in B cell maturation. *J. Immunol.* 121:685.

Rosenstreich, D.L. and S.N. Vogel. 1980. Central role of macrophages in the host response to endotoxin. In: *Microbiology 1980*. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C.

Rosner, M.R., J. Tang, I. Barzilay, and H.G. Khorana. 1979. Structure of the lipopolysaccharide from an *Escherichia coli* heptose-less mutant. I. Chemical degradations and



identification of products. *J. Biol. Chem.* 254:5906.

Rubinstein, S., P.C. Familletti, and S. Pestka. 1981. Convenient assay for interferons. *J. Virol.* 37:755.

Ryan, J.L. and K.P.W.J. McAdam. 1977. Genetic non-responsiveness of murine fibroblasts to bacterial endotoxin. *Nature* 269:153.

Scheid, M.P., M.K. Hoffmann, K. Komuro, U. Hammerling, J. Abbott, E.A. Boyse, G.H. Cohen, J.A. Hooper, R.S. Schulof, and A.L. Goldstein. 1973. Differentiation of T cells induced by preparations from thymus and by nonthymic agents. *J. Exp. Med.* 138:1027.

Scher, I. 1982. The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunity. *Adv. Immunol.* 33:1.

Schlessinger, J., I. Lax, Y. Yarden, H. Kanety, and T. Libermann. 1984. Monoclonal antibodies against the membrane receptor for epidermal growth factor: A versatile tool for structural and mechanistic studies. In: *Monoclonal antibodies to receptors: Probes for receptor structure and function.* M.F. Greaves (ed.). Chapman and Hall, New York. p.281.

Schlessinger, J., Y. Shechter, M.C. Willingham, and I. Pastan.

1978. Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells. Proc. Natl. Acad. Sci. U.S.A. 75:2659.

Sidorczyk, Z., U. Zähringer, and E.T. Rietschel. 1983. Chemical structure of the lipid A component of the lipopolysaccharide from a *Proteus mirabilis* Re mutant. Eur. J. Biochem. 137:15.

Siegel, S. 1956. Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill Book Company, Inc., New York. p. 127.

Sipe, J.D. and D.L. Rosenstreich. 1981. Serum factors associated with inflammation. In: Cellular functions in immunity and inflammation. J. Oppenheim, D.L. Rosenstreich, M. Potter (eds.). Elsevier-North Holland, New York. p. 411.

Skarnes, R.C. and M.J.K. Harper. 1972. Relationship between endotoxin-induced abortion and the synthesis of prostaglandin F2 $\alpha$ . Prostaglandins 1:191.

Springer, G.F. and J.C. Adye. 1975. Endotoxin binding substances from human leukocytes and platelets. Infect. Immun. 12:978.

Staber, G.F. 1980. Diminished response of

granulocyte-macrophage colony-stimulating factor (GM-CSF) in mice after sensitization with bacterial cell-wall components. Exp. Hematol. 8:120.

Stanley, E.R. and L.J. Guilbert. 1980. Regulation of macrophage production by a colony stimulating factor. In: Mononuclear Phagocytes - Functional Aspects, Part I. R. van Furth (ed.). Martinus Nijhoff. The Hague, Netherlands. p.415.

Stieritz, D.D. and I.A. Holder. 1975. Experimental studies of the pathogenesis of infection due to Pseudomonas aeruginosa: description of a burned mouse model. J. Infect. Dis. 131:689.

Sullivan, R., P.J. Gans, and L.A. McCarrill. 1983. The synthesis and secretion of granulocyte-monocyte colony-stimulating activity (CSA) by isolated monocytes: kinetics of the response to bacterial endotoxin. J. Immunol. 130:800.

Sultzzer, B.M. 1969. Genetic factors in leucocyte responses to endotoxin: Further studies in mice. J. Immunol. 103:32.

Sultzzer, B.M. and B.S. Nilsson. 1972. PPD tuberculin -- a B cell mitogen. Nature (London) New Biol. 240:199.

Sumner, M.A., T.R. Bradley, G.S. Hodgson, M.J. Cline, P.A. Fry,

and L. Sutherland. 1972. The growth of bone marrow cells in liquid culture. Br. J. Haematol. 23:221.

Suter, E., G.E. Ullman, and R.G. Hoffman. 1958. Sensitivity of mice to endotoxin after vaccination with BCG (*Bacillus Calmette-Guerin*). Proc. Soc. Exp. Biol. Med. 99:167.

Takayama, K., N. Qureshi, E. Ribi, and J.L. Cantrell. 1984. Separation and characterization of toxic and non-toxic forms of lipid A's. Rev. Infect. Dis. 6:439.

Trudgett, A., T.A. McNeill, and M. Killen. 1973. Granulocyte-macrophage precursor cell and colony-stimulating factor responses of mice infected with *Salmonella typhimurium*. Infect. Immun. 8:450.

Ulevitch, R.J., A.R. Johnson, and D.B. Weinstein. 1979. New function for high density lipoproteins: Their participation in intravascular reactions of bacterial lipopolysaccharides (LPS). J. Clin. Invest. 64:1516.

Ulevitch, R.J., A.R. Johnson, and D.B. Weinstein. 1981. New function for high density lipoproteins (HDL). II. Isolation and characterization of a bacterial lipopolysaccharide-HDL complex formed in rabbit plasma. J. Clin. Invest. 67:827.

Ulevitch, R.J., P.S. Tobias, and J.C. Mathison. 1984.

Regulation of the host response to bacterial lipopolysaccharide. Fed. Proc. 43:2755.

Urbaschek, B. and A. Nowotny. 1968. Endotoxin tolerance induced by detoxified endotoxin (endotoxoid). Proc. Soc. Exp. Biol. Med. 127:650.

Urbaschek, R.M., R.K. Shadduck, C. Bona, and S.E. Mergenhagen. 1980. Colony-stimulating factor in nonspecific resistance and in increased susceptibility to endotoxin. In: Microbiology 1980. D. Schlessinger (ed.). American Society for Microbiology, Washington, D.C. p.115.

Van Waarde, D., E. Hulsing-Hesselink, and R. van Furth. 1978. Humoral control of monocytopoiesis by an activator and an inhibitor. Agents and Actions 8:432.

Vogel, S.N., K.E. English, and A.D. O'Brien. 1982. Silica enhancement of murine endotoxin sensitivity. Infect. Immun. 38:681.

Vogel, S.N., C.T. Hansen, and D.L. Rosenstreich. 1979. Characterization of a congenitally LPS-resistant, athymic mouse strain. J. Immunol. 122:619.

Vogel, S.N., M.L. Hilfiker, and M.J. Caulfield. 1983. Endotoxin-induced T lymphocyte proliferation. J. Immunol.

130:1774.

Vogel, S.N. and S.E. Mergenhagen. 1982. Cellular basis of endotoxin susceptibility. In: Host-Parasite Interactions in Periodontal Diseases. R.J. Genco and S.E. Mergenhagen (eds.). American Society for Microbiology, Washington, D.C. p.160.

Vogel, S.N., R.N. Moore, J.D. Sipe, and D.L. Rosenstreich. 1980. BCG-induced enhancement of endotoxin sensitivity in C3H/HeJ mice. I. In vivo studies. J. Immunol. 124:2004.

Vogel, S.N. and D.L. Rosenstreich. 1981. LPS-unresponsive mice as a model for analyzing lymphokine-induced macrophage differentiation in vitro. In: Lymphokines, Vol. 3. E. Pick and M. Landy (eds.). Academic Press, New York. p.149.

Vogel, S.N., A.C. Weinblatt, and D.L. Rosenstreich. 1981. Inherent macrophage defects in mice. In: Immunologic Defects in Laboratory Animals. M.E. Gershwin and B. Merchant (eds.). Plenum Press, New York. p.327.

Volkman, A. and J.L. Gowans. 1965. The origin of macrophages from bone marrow in the rat. Brit. J. Exp. Path. 46:62.

Warren, M.K. and S.N. Vogel. 1985. Bone marrow-derived macrophages: Development and regulation of differentiation markers by colony stimulating factor and interferons. J.

Immunol. 134:982.

Watson, J., K. Kelly, M. Lergen, and B.A. Taylor. 1978. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J. Immunol. 120:422.

Watson, J., K. Kelly, and C. Whitlock. 1980. Genetic control of endotoxin sensitivity. In: Microbiology 1980. D. Schlessinger (ed.). American Society for Microbiology. Washington, D.C. p. 4.

Watson, J. and R. Riblet. 1974. Genetic control of responses to bacterial lipopolysaccharides in mice. I. Evidence for a single gene that influences mitogenic and immunogenic responses to lipopolysaccharide. J. Exp. Med. 140:1147.

Weinbaum, G., S. Kadis, and S.J. Ajl. 1971. Microbial toxins, Vol. IV. Academic Press Inc., New York.

Weinstein, M.J., J.A. Waitz, and P.E. Cane. 1970. Induction of resistance to bacterial infection of mice with poly I-poly C. Nature (London) 226:170.

Westphal, O. and O. Lüderitz. 1954. Chemische Erforschung von Lipopolysacchariden gramnegativer Bakterien. Angew. Chem. 66:407.



Wharton, D.R.A. and H.J. Creech. 1949. Further studies of the immunological properties of polysaccharides from Serratia marcescens (Bacillus prodigiosus). II. Nature of the antigenic action and the antibody response in mice. J. Immunol. 62:135.

Wilkinson, S.G. 1977. Composition and structure of bacterial lipopolysaccharides. In: Surface carbohydrates of the prokaryotic cell. I.W. Sutherland (ed.). Academic Press, New York. p.97.

Williams, Z., C.F. Hertogs, and D.H. Pluznik. 1983. Use of mice tolerant to lipopolysaccharide to demonstrate requirement of cooperation between macrophages and lymphocytes to generate lipopolysaccharide-induced colony stimulating factor in vivo. Infect. Immun. 41:1.

Young, L.S. 1979. Gram negative sepsis. In: Principles and practice of infectious diseases. G.L. Mandell, R.G. Douglas, Jr., J.E. Bennett (eds.). Wiley, New York. p.571.

Youngner, J.S. and W.R. Stinebring. 1965. Interferon appearance stimulated by endotoxin, bacteria, or viruses in mice pretreated with Escherichia coli endotoxin or infected with Mycobacterium tuberculosis. Nature (London). 208:456.

Zaldivar, N.M. and I. Scher. 1979. Endotoxin lethality and tolerance in mice: Analysis with the B-lymphocyte-defective

CBA/N strain. Infect. Immun. 24:127.

Zimmerman, D.H., S. Gregory, and M. Kern. 1977.

Differentiation of lymphoid cells: The preferential binding of the Lipid A moiety of lipopolysaccharide to B lymphocyte populations. J. Immunol. 119:1018.

Zollinger, W.D., D.L. Kasper, B.J. Vetri, and M.S. Artenstein. 1972. Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect. Immun. 6:835.